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Ionizing radiation (IR) is the primary adjuvant treatment for glioblastoma multiforme (GBM), 
the most aggressive primary brain tumor in adults.  Enhancement of the effects of IR may 
increase patient survival and quality of life in patients with GBM.  The repair of DNA double 
strand breaks (DSBs) produced by IR proceeds along two pathways, nonhomologous end-joining 
(NHEJ) and homologous repair (HR).  The herpes simplex virus (HSV) immediate-early protein, 
ICP0, has been shown to induce the degradation of the catalytic subunit of DNA-dependent 
protein kinase (DNA-PKcs).  DNA-PKcs is the primary component of NHEJ, the major DNA 
DSB repair pathway in mammalian cells.  A replication-defective HSV-1 vector, d106, which 
solely expresses the immediate-early (IE) protein, ICP0, was used to determine the effect of 
ICP0 on GBM cell survival and DNA repair after IR treatment.  Preinfection of two 
radioresistant GBM cells lines by d106 resulted in decreased cell survival and proliferation, 
protein degradation of DNA-PKcs, inhibition of DNA DSB repair, and enhanced apoptosis 
following IR.  Optimal intracerebral delivery of the HSV-1 mutant, d106, was established by 
convection-enhanced delivery (CED) in a mouse model.  Translation of the effects of ICP0 in 
combination with IR was performed with CED of d106 in a mouse glioma model.  CED of d106 
in combination with whole-brain irradiation significantly increased animal survival.   
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1. INTRODUCTION 
 
1.1. Overview 
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults.  The 
incidence of GBM is dwarfed by the incidence of patients with lung, colon, or breast cancer, but 
GBM may be the most devastating and therapy resistant of all malignancies.  Despite over four 
decades of advances in microneurosurgery, ionizing radiation (IR) therapy, radiology imaging, 
and the introduction of novel chemotherapeutic agents, the prognosis is poor (65, 184, 191, 234, 
264, 268, 333) (237, 292).  The median life expectancy of patients with GBM is 12 months; only 
5% of patients or fewer will be alive five years after diagnosis (25, 331).  Systemic metastases 
can occur with GBM but are relatively rare.  The tumors are extremely aggressive in a locally 
invasive fashion.  After treatment, the majority of tumors recur within two centimeters of their 
original tumor margin (145).  On magnetic resonance (MR) imaging, infiltrating tumor cells 
extend beyond the area of contrast enhancement (165).  The goal of surgical resection is to 
remove the contrast-enhancing portion of the tumor due to the potential morbidity from 
removing adjacent normal neural tissue (140, 166).  All resections of GBMs leave behind 
nonenhancing infiltrative tumor cells that reside away from the primary tumor mass.  These 
tumor cells are responsible for recurrence and the ultimate demise of patients with GBM.   
Radiation therapy remains the sole agent that increases the survival of patients with GBM 
(191, 330, 331).  IR exerts its lethal effects on cells primarily by inducing DNA double-strand 
breaks (DSBs).  Both adult primary (de novo) and secondary GBMs are remarkably resistant to 
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IR treatment.  The limited efficacy of radiation treatment is believed to arise from the poor 
apoptotic response to IR by the tumor cells and the hypoxic environment present within tumors 
(84, 164, 167, 353, 356).   
Herpes simplex virus 1 (HSV-1) is a large, neurotropic DNA virus that has been studied 
for use in the therapy of human GBM.  A large number of HSV-1 genes have been shown to be 
non-essential and can be deleted from the genome to provide additional room for potential gene 
insertions.  A number of different genetically engineered viruses have been constructed with 
deletions or mutations in one or more HSV genes (e.g. γ134.5, UL39 [ribonucleotide reductase], 
thymidine kinase [tk], and UTPase) in an effort to decrease toxicity of HSV to the central 
nervous system (CNS) and provide a condition for viral replication only in replicating cells that 
can provide cellular homologues (49, 51, 152, 208, 222).  Several phase I clinical trials have 
been completed for use of the conditionally-replicative HSV mutants G207 and 1716, on patients 
with recurrent malignant gliomas failing IR treatment (134, 206, 252, 271).  All clinical studies 
performed have shown little overall efficacy, and delivery of HSV-1 to the brain by stereotactic 
injection has been a limiting factor.  
New therapeutic strategies need to be developed for improved long-term management of 
GBM.  Multi-modal treatment approaches are required which attack the molecular and biological 
features of malignant gliomas.  Enhancement of the effects of IR treatment, by inhibition of 
DNA repair, may allow for better tumor control.  Since these tumors rarely metastasize away 
from the nervous system and the majority recur in a local fashion, local tumor control must be 
achieved to significantly extend the survival of patients with GBM.  Convection-enhanced 
delivery (CED) is an approach developed to overcome the obstacles associated with current CNS 
agent delivery (26, 230) and is increasingly used to distribute therapeutic agents for treatment of 
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malignant gliomas.  Currently, multiple clinical trials involve CED for the treatment of recurrent 
GBM (182, 326, 336, 338).   
The study presented here identifies the HSV-1 immediate-early (IE) protein, ICP0, as an 
inhibitor of DNA repair that enhances the radiosensitivity of experimental human glioblastoma 
multiforme.  Optimal intracerebral delivery of the ICP0-producing virus, d106, was developed in 
a mouse model by CED.  Translation of the in vitro effects of ICP0 was performed by CED of 
d106 in a mouse glioma model in combination with IR.   
 
1.2. Glioblastoma Multiforme 
 
1.2.1. Astrocyte Differentiation and Glioma Formation 
The mammalian CNS is composed of two main cell populations:  neurons and glia.  Glial cells 
are further divided into three subpopulations with distinctive morphologies and functions:  (1) 
astrocytes, (2) oligodendrocytes, and (3) microglia.  Astrocytes are the most abundant glia type 
in the CNS, and they fulfill various important functions, including supporting and protecting 
neurons, inducing neurogenesis, regulating synapse formation and transmission, and initiating 
immune responses (63).   
Multipotent, self-renewing neuroepithelial stem cells give rise to glial cells in response to 
both extracellular and intracellular stimuli (63).  Extracellular stimuli include growth factors and 
cytokines, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), ciliary neurotrophic factor/leukemia inhibitory factor 
(CNTF/LIF), bone morphogenetic protein, interleukin-6 (IL-6), and sonic hedgehog (SHH).  
EGF, FGF, and PDGF act as mitogens to confer neural progenitors the self-renewal capacity 
during multilineage differentiation (170, 323).  EGF signaling also induces astroglial 
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differentiation.  Epidermal growth factor receptor (EGFR) overexpression in neural progenitors 
has been shown to lead to an increase in the number of astrocytes while loss of EGFR expression 
in mice delays astrocyte differentiation and decreases astrocyte numbers (174).   
Gliomas are a group of CNS neoplasms with distinct histologic characteristics, 
comprising almost 60% of total human CNS malignancies.  Gliomas are classified into two 
major groups: astrocytomas and oligodendrogliomas.  Glioblastoma multiforme (GBM) is a 
tumor derived from astrocytes and is classified in the group of gliomas known as the diffuse 
(infiltrating) astrocytomas.  The diffuse astrocytomas are classified into three malignancy grades:  
grade 2 (astrocytoma), grade 3 (anaplastic astrocytoma), and grade 4 (GBM).  GBM is the most 
common diffuse astrocytoma, representing 82% of these cases diagnosed in the United States.  
Among all neuroepithelial tumors, GBM is the most common and represents nearly half of all 
cases. 
 
1.2.2. GBM Incidence, Classification, and Molecular Genetics 
GBM is the most common primary brain tumor, accounting for more than 60% of all primary 
brain tumors.  Approximately 10,000-15,000 new cases of GBM are diagnosed in the United 
States yearly (64, 315).  The incidence of GBM is 7.7 cases/100,000 person-years.  GBM may 
manifest at any age, but preferentially affects adults, with a peak incidence between 45 and 70 
years.   
GBM can be divided into at least two subgroups based on the genetic makeup of the 
tumor.  Primary GBM arises de novo clinically and most often occurs in elderly patients.   It is 
characterized genetically by over-expression (80% of cases) or amplification (40% of cases) of 
the epidermal growth factor receptor gene (EGFR), which encodes a tyrosine kinase involved in 
cell replication (Fig. 1) (107, 137, 185, 199, 327, 334).  Notably, p53 mutation almost never 
 5 
occurs in primary GBMs with EGFR amplification (272).  Approximately 10% of primary 
GBMs have amplification of MDM2 (murine double minute 2), a transcriptional target of p53 
(199).  Other genetic alterations include retinoblastoma (Rb) gene mutations on chromosome 13, 
loss of p15 (CDKN2B) and p16 (CDKN2A) on chromosome 9, and mutation or deletion of 
PTEN (phosphatase and tensin homology) on chromosome 10 (Fig.1). Close association of 
EGFR amplification and p15/p16 deletions, occurring primarily in elderly patients with primary 
GBM without a p53 mutation, may contribute to the worst prognosis of elderly GBM patients.  
The pattern of genetic alterations in primary pediatric GBM is distinct from that of adult GBM.  
Amplification of EGFR or MDM2 proto-oncogenes and p15/p16 deletions occur randomly and 
nonsequentially in pediatric GBM (177).  Instead, p53 alterations have been found in 
approximately 50% of cases (31, 314).  Overexpression of p53 in primary pediatric GBM is 
strongly associated with adverse outcome, independent of clinical prognostic factors and 
histologic findings (263). 
Secondary GBM arises in a younger population through progression from a lower-grade 
glioma (World Health Organization (WHO) grade II and III) and accounts for approximately one 
third of GBM tumors (250).  Numerous genetic alterations accumulate and become linked 
together sequentially to parallel malignant progression.  Secondary GBM is characterized by 
mutation and inactivation of the p53 gene and overexpression of PDGF ligands and receptors 
(Fig. 1).  These steps occur early in secondary GBM tumorigenesis.  The subsequent loss of 
chromosomes 1, 9p, 13q, and 19q are considered to be major events in tumor progression.  
Transition from anaplastic astrocytoma (WHO grade III) to secondary glioblastoma (WHO grade 
IV) requires the loss of chromosome 10q (PTEN deletion). 
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Figure 1.  GBM cell signaling.  
1.2.2.1. Growth Factor Signaling Pathways, Mouse Modeling, and GBM 
The frequent overexpression of growth factors and their receptors or activating mutations of 
these receptors in GBM suggests the constitutive activation of receptor tyrosine kinase signaling 
pathways in these tumors (63).  Elevated RAS and AKT activities, which are downstream targets 
of tyrosine kinase receptors, occur in GBM cells (Fig. 1) (121, 123).  Activation of the RAS 
pathway is causally related to tumorigenesis in a mouse model.  Overexpression of an active 
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form of RAS from the glial fibrillary acidic protein (GFAP) promoter in astrocytes induces 
astrocytoma formation in mice (75).  Similarly, overexpression of v-SRC, which is capable of 
activating RAS from the same promoter also generates astrocytomas in mice (340, 341). 
Simultaneous activation of the RAS and AKT pathways has been shown to induce GBM 
formation in nestin positive CNS progenitor cells (147).  The combination of these two signaling 
pathways is essential, as gene transfer of neither active K-RAS nor AKT alone into the CNS 
progenitors is able to induce GBM formation.  Even though elevated AKT and RAS activities are 
present in human gliomas and are causally related to GBM formation in mice, no activating 
mutations of either RAS or AKT have ever been documented in human GBM tumors (63).  
Elevation of RAS and AKT activities is due to the sustained activation of upstream receptor 
tyrosine kinases (207) and the inactivation of key negative regulators for these two signaling 
pathways, such as PTEN for the PI3K/AKT pathway (306) and RAS-like inhibitor of growth for 
the RAS/MAPK pathway (83). 
 
1.2.2.2. Deregulation of Cell Cycle Arrest Pathways and GBM 
Mutations that lead to disruption of cell cycle arrest pathways are also found in human GBM 
(63).  The most common mutation is deletion of the INK4A-ARF locus (155).  The INK4A-ARF 
locus, known to encode both p16INK4A and p14ARF proteins (p19ARF in mice), is one of the major 
regulators of cell cycle progression (Fig. 1).  Homozygous deletion of the INK4A-ARF locus in 
mice results in the breakdown of G1/S and G2/M cell cycle checkpoints (148). 
The p53 gene is another target mutated in human GBM tumors (Fig. 1) (163).  Mutations of 
p53 are frequently associated with either amplification of CDK4 or loss of retinoblastoma (Rb) 
activity, indicating disruption of both pathways is important in the biology of GBM (247). 
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1.2.3. GBM Clinical Features, Prognosis, and Histopathology 
The clinical history of the disease is usually short (less than 3 months in more than 50% of 
cases), unless the neoplasm has developed from a lower-grade astrocytoma.  Patients often 
present after an epileptic seizure with non-specific neurological symptoms, headache, and 
personality changes.  As the tumor rapidly enlarges, brain distortion by tumor mass effect and 
resultant edema can lead to an elevation in intracranial pressure.  Patients with large tumors can 
present with motor/sensory symptoms and/or a change in the level of consciousness. 
The median life expectancy of patients with GBM is 12 months; only 5% of patients or 
fewer will be alive at five years after diagnosis (25, 331) despite treatment.  Several variables 
affect the prognosis of patients with GBM, including age (36), preoperative performance status 
(115), tumor location (110), reoperation for recurrent tumor (8, 135), and whether the patient 
receives radiation therapy (331).   
GBM tumors occur most often in the subcortical white matter of the cerebral 
hemispheres.  Tumor infiltration extends into adjacent cortex, the basal ganglia, and the 
contralateral hemisphere.  Glioblastomas of the brainstem are infrequent and often affect 
children.  GBM tumors are composed of poorly differentiated neoplastic astrocytes that are 
pleomorphic and contain nuclear atypia with brisk mitotic activity (171).  Tumors are quite 
vascular characterized by microvascular proliferation, consisting of smooth muscle/pericyte and 
endothelial cell proliferation.  The association of microvascular proliferation and necrosis is a 
histopathological hallmark of glioblastomas.   
Glioblastomas are notorious for their rapid invasion of neighboring brain structures (37).  
A very common feature is extension of the tumor through the corpus callosum into the 
contralateral hemisphere, creating the image of a bilateral symmetrical lesion (‘butterfly 
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glioma’).  Similarly, rapid spread is observed in the internal capsule, fornix, anterior 
commissure, and optic radiation.  These structures may be enlarged and distorted, serving as a 
‘passageway’ for the formation of new tumor masses in other sites of the brain leading to 
multifocal glioblastoma.  Metastasis of GBM to other sites of the body is very rare. 
 
1.2.4. GBM and Surgical Resection 
The goals of surgical resection of GBM include histologic diagnosis, relief of tumor mass effect, 
and cytoreduction.  Due to the work of Kelly et al., complete surgical resection of GBM tumors 
was determined unlikely because of tumor infiltration with normal brain (165, 166).  Kelly 
described three contiguous regions of a GBM tumor:  (1)  the contrast-enhancing portion on MRI 
that corresponds to the tumor cell mass without intervening brain parenchyma,  (2)  the area 
found in the center of the enhancing mass on MRI that represents necrotic tumor cells, and (3)  
the areas of increased signal intensity surrounding the enhancing portion of the tumor, which 
represent isolated tumor cell infiltration into the brain parenchyma.  The density of infiltrating 
cells may vary in these areas from nearly all tumor cells to rare scattered cells with a 
predominance of edema.  Surgical resections of GBM are aimed at removing the enhancing 
portion of the tumor along with the necrotic center.  All resections of GBMs leave behind 
nonenhancing infiltrative tumor cells that reside away from the primary tumor mass.  These 
tumor cells are ultimately responsible for recurrence of GBM tumors almost always in a local 
fashion. 
The extent of tumor resection that should be undertaken in patients with GBM is 
controversial.  Rigorous reviews of the literature have revealed there is little scientific evidence 
that aggressive surgical management significantly prolongs survival (141, 234, 268).  One recent 
multivariate analysis of 416 patients with GBM revealed a significant survival advantage in 
 10 
patients who underwent surgical resection of 98% or more of their tumor volume (184).  The 
median survival for patients undergoing ≥ 98% of the enhancing portion of the tumor was 13.4 
months, whereas for patients with lesser resections, the median survival was 8.8 months.  The 
optimal extent of resection in any patient depends on the tumor size and location, the patient’s 
general and neurological status, and the experience of the surgeon. 
 
1.2.5. GBM and Ionizing Radiation 
The first promising data demonstrating the efficacy of radiotherapy after surgery for malignant 
gliomas in a randomized clinical trial was reported in 1976 by the Brain Tumor Study Group 
(BTSG), also known as the Brain Tumor Cooperative Group (BTCG) (329, 330).  The BTSG 
established a benefit for postoperative radiotherapy after demonstrating a 37.5 week median 
survival in whole-brain radiotherapy alone versus 17 and 25 weeks for patients treated with 
conventional care and chemotherapy (BCNU, also known as carmustine), respectively.  BCNU 
and whole-brain radiation therapy produced a 40.5 week median survival (330).  GBM 
constituted 90% of patients in this trial.  Sixty Gy IR in fractionated doses remains the standard 
of care for patients with newly diagnosed GBM.   
Over the last 20 years, attempts have been made to improve the efficacy of IR through 
dose escalation using increased doses of standard fractionation, hyperfractionation, interstitial 
brachytherapy, three-dimension conformal radiotherapy, and stereotactic radiosurgery.  
Unfortunately, no significant increase in survival has been shown with these strategies.  Partial 
brain radiotherapy has replaced whole-brain radiotherapy for patients with GBM based on data 
showing recurrence of GBM occurs within 2 cm of the primary tumor site in 90% of cases (145). 
The limited efficacy of IR treatment is believed to arise from the poor apoptotic response 
to IR by the tumor cells and the hypoxic environment present within tumors (84, 164, 167, 353, 
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356).  Glioma cells show an absence of either significant induction of bax or repression of bcl-2 
and bcl-XL after irradiation (176, 298).  Strategies reported to enhance apoptosis after irradiation 
of malignant glioma cells include exogenous transfer of p53, APAF-1, and caspase 9 (116, 186, 
297).  Radiation-induced apoptosis in most cell types other than glial cells has been shown to 
depend on the presence of wild-type (wt) p53 (200).  The presence or absence of wt p53 has not 
been shown to have a significant impact on the radiosensitivity of GBM cells (14, 125).  
Recently, autophagic cell death has been introduced as a possible mechanism for GBM cell death 
after IR, characterized by the accumulation of acidophilic vesicular organelles (AVOs) in the 
cytoplasm (353).  Studies have shown that GBM cells with wt p53 exhibit a radiation-induced 
cell-cycle G1 arrest in contrast to cells lacking wt p53 (125, 356).  These cells resume 
proliferation after several weeks, correlating with results from clinical studies demonstrating 
transient inhibition of tumor growth followed by regrowth within 6 to 8 months after irradiation 
of the lesion (125, 353).  A deficit in G1-checkpoint after IR may be a mechanism for 
radioresistance in GBM cells lacking wt p53 (124).  Radioresistance of GBMs with wt p53 may 
be due to a dysfunctional p53 pathway with overexpression of p21 and failure of transcriptional 
activation of p21 in response to irradiation (176).  Nevertheless, IR continues to be the primary 
adjuvant treatment modality and standard of care for GBM patients as survival is modestly 
increased (331). 
 
1.2.6. GBM and Chemotherapy 
Chemotherapy has produced little success in the treatment of GBM (256).  Nitrosoureas are the 
main chemotherapeutic agents used in the treatment of malignant gliomas.  At present, 
chemotherapy usually is reserved for the palliative treatment of patients who have recurrent 
disease.  Even though the blood-brain barrier is not entirely intact in these tumors, the blood-
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tumor barrier prevents many chemotherapy agents from reaching the tumor in sufficient 
concentration (343).  The invasive nature of GBM results in malignant cells at the periphery of 
the tumor being associated with a normal blood-brain barrier, providing protection from 
chemotherapeutic agents.  Intra-arterial infusion of chemotherapeutic agents after blood-brain 
barrier disruption has been attempted resulting in continued toxicity and limited clinical success 
(77, 239, 294).  Biodegradable wafers impregnated with BCNU (GLIADEL; Guilford 
Pharmaceuticals, Inc.) can be used to line the resection cavity after GBM resection is performed.  
Modest prolonged survival has been shown with the use of GLIADEL wafers in GBM patients 
(34, 35, 322).  The U.S. Food and Drug Administration has approved the use of these wafers for 
the treatment of recurrent and newly diagnosed GBM tumors. 
Temozolomide (TMZ; Schering-Plough, Inc.), a novel alkylating agent, recently has been 
introduced to the clinical setting and demonstrated activity in recurrent gliomas (104, 311, 357).  
After oral administration, TMZ is rapidly absorbed with almost 100% bioavailability (238).  It 
readily crosses the blood-brain barrier and achieves effective concentrations in the cerebrospinal 
fluid (CSF).  In a phase II trial in patients with recurrent GBM, the 6-month progression-free 
survival rate in temozolomide-treated patients was 18% and the 6-month overall survival rate 
was 46% (29).  A total of 53% of patients experienced a clinical benefit with TMZ treatment.  
Resistance to TMZ is mediated in part by the DNA repair enzyme, methylguanine-DNA 
methyltransferase (MGMT).  This enzyme has been found to be a major determinant of TMZ 
cytotoxicity in vitro and continuous exposure to TMZ leads to depletion of MGMT (105).  
Methylation of the MGMT promoter has been associated with greater overall survival in GBM 
patients treated with TMZ (138, 139). 
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1.2.6.1. GBM and Chemoradiation 
The combination of TMZ and IR, termed chemoradiation, has been shown to have additive and 
synergistic activity in vitro against glioblastoma cells (324, 337).  It has been shown that TMZ 
induces a G2-M arrest in glioma cells allowing for cell cycle synchronization in a radiosensitive 
phase (142).  Chemoradiation is a new standard of care now evolving for patients with newly 
diagnosed GBM (312, 313).  Based on promising results from a randomized phase III trial, the 
use of concomitant and adjuvant TMZ chemotherapy and radiotherapy significantly improves 
progression-free and overall survival in GBM patients (312, 313).  Patients randomized between 
standard IR treatment versus IR treatment and concomitant TMZ followed by up to 6 cycles of 
adjuvant TMZ had an increase in median survival of 3 months (P<.0001) in the TMZ-treated 
group. 
 
1.2.6.2. Convection-Enhanced Delivery 
Distribution of therapeutic agents within the CNS has been problematic.  Systemic delivery is 
limited by the blood-brain barrier, nontargeted distribution, and systemic toxicity.  Diffusion-
dependent methods that deliver substances by “push-pull” catheters (232), intrathecal injection 
(181), miniosmotic pumps (201), and drug-impregnated polymers (211) (34) can result in 
nontargeted distribution and a volume of distribution (Vd) that is limited by molecular weight 
and infusate diffusivity.  CED is an approach developed to overcome the obstacles associated 
with current CNS agent delivery (26, 230) and is increasingly used to distribute therapeutic 
agents for treatment of malignant gliomas.  Currently, multiple clinical trials involve CED for the 
treatment of recurrent GBM (182, 326, 336, 338).  In CED, a small hydrostatic pressure 
differential imposed by a syringe pump to distribute infusate directly to small or large regions of 
the CNS is used in a safe, reliable, targeted, and homogeneous manner (60).  CED relies on bulk 
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flow that is driven by a small gradient to distribute molecules within the interstitial spaces of the 
CNS.  CED allows for a clinically effective Vd that is linearly proportional to the volume of 
infusion (Vi).  Convection is not limited by the infusate’s molecular weight, concentration, or 
diffusivity (26, 230, 310).  Since CED directly distributes molecules within brain parenchyma, it 
can be used to target select regions of the CNS in a manner that bypasses the blood-nervous 
system barrier (253).  
 
1.2.7. Gene Therapy for GBM 
Malignant brain tumors were one of the earliest targets for human gene therapy.  Brain tumor 
cells represent islands of high mitotic activity on the background of a predominantly postmitotic 
environment in the adult brain.  Treatments with selective tumor toxicity can be designed 
accordingly.  The best explored approach has been insertion of a genetic sequence into tumor 
cells which renders these and their clonal progeny sensitive to drug treatment (226).  The 
transgene/vector system widely used in the past decade was the herpes simplex virus thymidine 
kinase (HSV-tk) gene transferred by a replication-incompetent retrovirus vector (97, 227, 251).  
Tumor cell transduction with HSV-tk together with gancyclovir administration allows for tk 
phosphorylation of gancyclovir to form a toxic nucleotide analog that is incorporated into 
replicating DNA causing strand termination and cell death by apoptosis (22).  Terminally 
differentiated cells, such as neurons in the brain, are spared because their DNA does not 
replicate.  In addition, sufficient activated gancyclovir can be transmitted across cell gap 
junctions to destroy neighboring untransduced tumor cells, a phenomenon known as the 
“bystander effect” (101, 348).  Early clinical trials using retrovirus vectors in combination with 
gancyclovir revealed the inability of these vectors to achieve a useful tumor tranduction rate 
(293).  Also, low viral titers (typically 1 x 105 – 107 infectious particles/ml) and instability of the 
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virus particles have limited the clinical usefulness of retroviral vectors (27).  Other 
nonreplicating recombinant viruses used in the treatment of GBM include HSV-1.  These viruses 
are deficient in immediate-early genes and express other HSV-1 genes (HSV-tk) and transgenes 
that can lyse tumor cells (244).   
Viruses have also been used as vectors and as oncolytic agents for human GBM tumors 
(48).  Replication conditional HSV-1 and adenovirus vectors have been engineered to replicate in 
mitotic cells only (e.g., HSV-1) or in cells lacking functional tumor-suppressor proteins such as 
p53 or Rb (e.g., adenovirus) (7, 208, 222).   
 
1.3. Ionizing Radiation 
 
1.3.1. Types and Quantity of Ionizing Radiation 
Radiation includes any kind of energy that is emitted from a source in the form of rays or waves. 
The absorption of energy from radiation in biological material may lead to excitation or to 
ionization.  The raising of an electron in an atom or molecule to a higher energy level without 
actual ejection of the electron is called excitation.  If the radiation has sufficient energy to eject 
one or more orbital electrons from the atom or molecule, the process is called ionization, and that 
radiation is said to be “ionizing radiation”.  The important characteristic of IR is the localized 
release of large amounts of energy.  The energy dissipated per ionizing event is approximately 33 
eV, which is more than enough to break a strong chemical bond.  For example, the energy 
associated with a C=C bond is 4.9 eV (130).  IR is classified as electromagnetic or particulate.  
Particulate radiation includes charged particles such as electrons, protons, α-particles, deuteron, 
negative π-mesons, and heavy charged ions.  Neutrons, which are uncharged, are also considered 
particulate radiation. 
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Electromagnetic radiation includes x- or γ-rays, radio waves, radar, radiant heat, and 
visible light.  X- and γ-rays do not differ in nature or in properties (130).  The designation x or γ 
reflects simply the way in which they are produced.  X-rays are produced extranuclearly, while 
γ-rays are produced intra-nuclearly.  X-rays are produced in an electrical device that accelerates 
electrons to high energy and then stops them abruptly in a target, usually made of tungsten or 
gold.  Part of the kinetic energy of the electrons is converted into x-rays.  Gamma-rays are 
emitted by radioactive isotopes and represent excess energy that is given off as the unstable 
nucleus breaks up and decays in its efforts to reach a stable form.  Both x- and γ-rays act in the 
same manner in biological systems.  They both may be thought of as a stream of photons, or 
“packets” of energy.  When x- or γ-rays are absorbed in living material, energy is deposited in 
the tissues and cells.  The energy is deposited unevenly in discrete packets.  The energy in a 
beam of x- or γ-rays is quantized into large individual packets, each of which is big enough to 
break a chemical bond and initiate the chain of events that culminates in a biological change. 
Quantity of IR is expressed in roentgens, rads, or gray.  The roentgen (R) is the unit of 
exposure and is related to the ability of x- or γ-rays to ionize air.  The rad is the unit of absorbed 
dose and corresponds to an energy absorption of 100 ergs/g.  In the case of x- and γ-rays an 
exposure of 1 R results in an absorbed dose in water or soft tissue roughly equal to 1 rad.  
Officially, the rad has been replaced as a unit by the gray (Gy), which corresponds to an energy 
absorption of 1 joule/kg.  Consequently, 1 Gy = 100 rads.   
 
1.3.2. Absorption and Action of Ionizing Radiation 
Ionizing radiation may be classified as directly or indirectly ionizing.  Charged particles, or 
particulate radiation, can directly disrupt the atomic structure of the biologic tissue through 
which they pass and produce chemical and biological changes.  Electromagnetic radiation (x- 
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and γ-rays) is indirectly ionizing.  They do not produce chemical and biological damage 
themselves, but when absorbed in the material through which they pass, they give up their 
energy to produce fast-moving charged particles. 
When x- or γ-rays, charged or uncharged particles are absorbed in biological material, 
there is a possibility they will interact directly with the critical targets in the cells.  The atoms of 
the target itself may be ionized or excited, leading to biological change.  This is what is termed 
the direct action of radiation and is the dominant process with neutrons or α-particles.  In direct 
action a secondary electron resulting from absorption of an x- or γ-ray photon interacts with 
cellular DNA to produce DNA damage.  Alternatively, radiation may interact with other atoms 
or molecules in the cell (mainly water) to produce free radicals that are able to diffuse far enough 
to reach and damage critical targets.  This is called the indirect action of radiation, which is the 
predominant mechanism of damage by x- or γ-rays.  A free radical is a free (not combined) atom 
or molecule carrying an unpaired orbital electron in the outer shell, which is highly reactive.  The 
major effector free radical, after radiation interaction with water, is a highly reactive hydroxyl 
radical (OH⋅).  Hydroxyl radicals are responsible for DNA damage after IR, producing DNA 
double- and single-strand breaks.  Approximately two thirds of DNA damage from x- or γ-rays is 
from the hydroxyl radical (130). 
 
1.3.3. DNA Double-Strand Breaks and Cell Response 
DNA double-strand breaks (DSBs) are the most critical form of DNA damage that may result in 
loss or rearrangement of genomic material and thereby lead to mutations, genomic instability, 
cancer development, or cell death (74, 146, 259, 347).  DSBs arise spontaneously during normal 
cell metabolism, such as meiotic and V(D)J recombination, but can also be induced by DNA 
damaging agents, such as IR and certain chemicals. 
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DNA DSBs activate an extensive array of responses that lead to damage repair and 
continuation of cellular life (Fig. 2) (157).  Ataxia telangiectasia mutated (ATM) protein is 
regarded as the primary activator of this network (296).  ATM is missing or inactivated in 
patients with the genetic disorder ataxia-telangiectasia (A-T), characterized by cerebellar 
degeneration, immunodeficiency, radiation sensitivity, chromosomal instability and cancer 
predisposition (21, 109).  Following the induction of DSBs, ATM’s kinase activity is enhanced 
and it phosphorylates key proteins in numerous signaling pathways, including the checkpoint 
kinases Chk1 and Chk2 and the DNA repair proteins 53BP1, BRCA1, and p53 (296).  The 
phosphorylation and accumulation of p53 after IR results in G1/S cell cycle arrest and p21 
induction (15, 39).  ATM’s activation was recently shown to involve dimer dissociation and 
intermolecular autophosphorylation on the serine 1981 residue (12).  ATM has also been shown 
to phosphorylate the histone variant, H2AX (38).  H2AX is rapidly phosphorylated (within 
seconds) when DSBs are introduced into mammalian cells, resulting in discrete γ-H2AX 
(phosphorylated-H2AX) foci at DNA damage sites (276).  Concomitant with ATM activation, a 
fraction of the nuclear content of ATM adheres to the DSB sites (9).  The mode by which the 
DSB signal is conveyed to ATM is not clear, nor are the proteins that function in the DSB 
response between damage induction and ATM activation. 
The MRN complex, whose core contains the Mre11, Rad50, and Nbs1 proteins, is 
involved in the initial processing of DSBs due to its nuclease activity and DNA binding 
capability (Fig. 2) (62).  These activities reside in the Mre11 protein, and partially depend on 
Mre11’s interaction with the Rad50 ATPase.  The Nbs1 protein is thought to be involved in the 
nuclear localization and proper assembly of the complex at DSB ends, probably via its ability to 
interact directly with γH2AX (173).  The MRN complex adheres to the sites of DSBs 
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immediately following their induction, and this process is independent of ATM (223).  The order 
in which ATM and the MRN complex act in the early phase of the DSB response is unclear.  
Functional MRN is required for ATM activation and timely activation of ATM-mediated 
pathways (321). 
 
Figure 2.  Production of DNA DSBs, cellular response, and repair. 
 
1.3.4. DNA Double-Strand Break Repair 
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DNA DSBs are repaired in eukaryotes by the concerted action of two repair pathways, 
homologous recombination (HR) and nonhomologous end-joining (NHEJ) (Fig. 2).  The MRN 
complex plays a role in both modes of repair, particularly in the HR pathway.  DSB repair by HR 
requires an undamaged template that contains a homologous DNA sequence, typically on the 
sister chromatid in the S or G2 phase of the cell cycle.  HR in higher eukaryotes is mediated by 
the gene products of the homologs to the Saccharomyces cerevisiae RAD52 epistasis group 
(275).  In contrast to HR, NHEJ of two double-stranded ends does not require an undamaged 
partner and does not rely on extensive homologies between the recombining ends (192).  NHEJ 
is active in all cell-cycle phases and is thought to repair the majority of DSBs in mammalian 
cells.  Defects in the NHEJ pathway can cause increased cell death secondary to DSBs generated 
by IR or restriction endonucleases (45, 278).  Additionally, defective or deregulated NHEJ may 
result in chromosomal aberrations, genomic instability, and ultimately contribute to cancer 
development (146, 347). 
 
1.3.4.1. NHEJ and DNA DSBs 
NHEJ can be an error-free or error-prone process, which is in part determined by different types 
of DNA ends.  Complementary cohesive ends typically generated by restriction endonucleases 
can be rejoined in an error-free manner by precise ligation.  NHEJ is commonly regarded as an 
error-prone process due the occurrence of end-processing (192).  This involves the alignment of 
overhanging ends by pairing along nucleotides of 1-4 bp microhomology that flank the break 
site, followed by gap filling or trimming of a few bases and subsequent ligation.  The repair of 
IR-induced DSBs is generally error-prone because IR destroys sequence information by causing 
complex DNA damage sites (347), thereby requiring end-modification prior to rejoining.  It is 
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largely unknown which regulatory proteins control the extent of DNA sequence alteration during 
repair. 
The DNA-dependent protein kinase (DNA-PK) complex and the XRCC4/DNA ligase IV 
complex are required for NHEJ (58).  DNA-PK, consisting of the Ku heterodimer (which 
consists of the Ku70 and Ku80 subunits) and the catalytic subunit (DNA-PKCS), is activated by 
DNA in vitro (Fig. 2) (301). DNA-PKCS is a member of the phosphatidylinositol-3 (PI-3)-like 
kinase family that includes ATM.  Ku binds to DNA ends with very high affinity and is thought 
to function as the DNA-binding and regulatory subunit that stimulates DNA-PKCS activity (118).  
The kinase activity of DNA-PK is required for the repair of DSBs by the NHEJ pathway (183).   
Recently, autophosphorylation of DNA-PKCS has been shown to occur in vivo in a Ku-
dependent manner in response to IR and is required for DSB repair (44).  Phosphorylated DNA-
PKCS has been shown to colocalize with both γH2AX and 53BP1 at sites of DNA DSBs.   
When assembled on a suitable DNA molecule in vitro, DNA-PKCS becomes activated and 
phosphorylates many transcription factors, including p53 (10).  DNA-PKCS serves as an 
upstream effector for p53 activation in response to IR, linking DNA damage to apoptosis (332).  
IR induction of apoptosis and Bax is significantly suppressed in the absence of DNA-PKCS. 
 
1.4. Herpes Simplex Virus 
 
1.4.1. Clinical HSV Infection and Treatment 
HSV is a well-adapted pathogen, demonstrated by its widespread prevalence in humans, its only 
known natural hosts.  Over 75% of all adults in the United States have antibodies to HSV-1 or 
35% to HSV-2.  Approximately 40 million infected individuals will experience recurrent herpes 
disease due to reactivation of their own “personal” viruses sometime in their lifetime.  HSV 
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initially gains access to the host via infection of epithelial cells at skin and/or mucosal surfaces 
leading to the production of characteristic painful vesicular lesions.  HSV-1 is associated with 
oral infection and is transmitted via oral and respiratory secretions while HSV-2 is generally 
associated with genital infection.   
HSV infection is associated with other infectious processes, including herpes keratitis and 
encephalitis.  Herpes keratitis can result in corneal blindness.  Due to HSV neurotropism, access 
to the CNS can cause encephalitis.  Herpes simplex encephalitis (HSE) occurs relatively 
infrequently, with an incidence of one case per 250,000 population/year in the United States 
(344).  It is the most commonly identified cause of acute viral encephalitis, comprising 20% of 
all cases (320).  There is a bimodal distribution of HSE, with 1/3 of cases occurring in those less 
than 20 years of age and 1/2 in those aged 50 years or more.  HSE occurs predominantly in 
neonates and immunocompromised individuals and is caused by HSV-2.  In immunocompetent 
adults, greater than 90% of cases of HSE result from infection with HSV-1, with the remainder 
due to HSV-2 infection.  HSV produces an acute, microhemorrhagic, necrotizing encephalitis 
with surrounding brain edema.  Predilection for bilateral temporal and orbitofrontal lobes of the 
brain occurs.  Asymmetric involvement of the insular cortex and cingulate gyrus can occur.  A 
proposed explanation for the typical pattern of involvement of the temporal and frontal lobes of 
the brain is the presence of the latent virus within the gasserian ganglion in Meckel’s cave (236).  
Reactivated virus may spread along the meninges around the temporal lobes and the 
undersurface of the frontal lobes.  A good outcome from HSV encephalitis relies on early 
diagnosis.  Delay in therapy or untreated HSV encephalitis has a high mortality rate (50% to 
75%), with little chance of full neurologic recovery (320).   
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Acyclovir is a nontoxic, prodrug antiviral that is highly efficacious against productive 
HSV infection (82).  Acyclovir is a nucleoside analog similar to guanosine, but contains an 
acyclic sugar group.  The drug requires three different kinases to be present in the cell to convert 
acyclovir to a triphosphate derivative, the actual antiviral drug.  High selectivity of the drug 
occurs with HSV-infected cells.  The first kinase that is required is a virus-encoded kinase called 
thymidine kinase (tk), which is not found in uninfected cells.  After initial phosphorylation by 
tK, subsequent phosphorylation is completed by cellular enzymes and acyclovir triphosphate is 
incorporated into DNA by the viral DNA polymerase.  DNA replication is blocked as acyclovir 
lacks a 3’-OH group. In addition, inactivation of viral DNA polymerase occurs.  Derivatives of 
acyclovir have been developed, including valacyclovir and famciclovir, which are used 
predominantly due to their greater efficacy from improved oral bioavailability (133). 
 
1.4.2. HSV Structure and Genome 
HSV consists of linear double-stranded DNA packaged into an icosadeltahedral capsid (106, 
149).  The capsid is surrounded by an amorphous tegument layer that is held within a trilaminar 
envelope containing glycoprotein spikes (122) (18, 304).  Glycoproteins are embedded in the 
trilaminar envelope of the mature virion (280). 
The HSV genome consists of 152 kilobase pairs comprising 84 genes and an excess of 90 
open reading frames (ORFs) (20, 169, 339).  Viral genes encode proteins that affect the 
coordinated expression of the viral genome.  In addition, proteins are expressed for viral 
replication and for virion surface and envelope components.  The viral genome is separated by a 
unique long (UL) and unique short (US) sequence flanked on each end by terminal inverted repeat 
sequences (214, 215).  The UL and US  sequences are covalently joined by internal repeat 
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sequences.  The UL and US sequences can randomly invert relative to each other so the HSV 
genome actually can exist in four equimolar isomers (136). 
 
1.4.3. HSV Life Cycle 
 
1.4.3.1. HSV Cell Entry 
HSV-1 infection involves virus attachment to the cell surface, fusion of the viral envelope with 
the plasma membrane, and entry of the viral capsid into the cytoplasm (228, 304).  The initial 
binding of HSV to the cell surface occurs by heparan sulfate (HS) proteoglycans present on the 
surface of most types of vertebrate cells (350).  HSV glycoproteins, B (gB) and C (gC) have 
been shown to be involved in the initial attachment phase through the interaction of positively 
charged glycoprotein structures with negatively charged HS moieties located on cell surface 
proteoglycans (187).  Removal of HS from the cell surface, either by enzymatic treatment or by 
selection of cell lines defective in the pathway HS, renders cells at least partially resistant to 
HSV infection by reducing virus attachment to the cell surface (119, 295).   
Following the initial adsorption event, a secondary binding event occurs between viral 
glycoprotein D and cellular receptors identified as herpesviral entry mediators, or HVEMs (114, 
225).  These include HveA, HveB (nectin-2), and HveC (nectin-1).  Fusion of the viral envelope 
with the cell membrane occurs after the binding of gD to its cognate cell surface receptor (228).  
Three other HSV glycoproteins have been implicated in the fusion process, including gB, gH, 
and gL (68, 72, 281).  Once fusion occurs, the nucleocapsid is released into the cell cytoplasm 
and viral capsids are transported to nuclear pores where viral DNA is released into the nucleus 
and viral gene expression can occur.  In certain cell types, HSV entry is dependent on 
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endocytosis and exposure to a low ph (242).  Inhibition of endocytosis has been shown to 
prevent uptake of HSV from HeLa and Chinese hamster ovary cells. 
 
1.4.3.2. HSV Pathogenesis 
Initial infection results in productive viral replication in cells of the epidermis and dermis (280).  
HSV may gain access to nerve termini of sensory neurons and is transmitted to the neuronal cell 
body by retrograde transport (55).  HSV can cause a latent infection in which the viral genome 
adopts a persistent, quiescent state.  Establishment of latency occurs predominantly in terminally 
differentiated, nondividing neurons of the peripheral nervous system that innervate the initial site 
of infection.  Neurons of sensory and autonomic ganglia are infected following primary rounds 
of replication in cells of mucosal or epidermal surfaces.  Since neurons neither replicate their 
DNA nor divide, the HSV genome does not need to replicate to persist.  HSV latent infection of 
peripheral neurons is an effective survival mechanism, as there are no vaccines or antivirals that 
can attack the latent infection.  Consequently, once the host is infected with HSV, the host is 
infected for life.   
Latency occurs when the cell represses immediate-early (IE) viral gene expression, 
inhibiting the cascade of early (E) and late (L) viral gene expression that lead to lytic infection 
(87).  In the latent state, the HSV viral genome circularizes (108, 156, 262), becomes associated 
with nucleosomes in a chromatin structure (73), and persists extrachromosomally (219).  Viral 
gene expression during latency is limited to a set of nontranslated RNA species, the latency 
associated transcripts (LATs), which are expressed as stable lariat intron RNA molecules and are 
detectable in the nuclei of latently infected neurons (59, 87, 305, 308).  Viral genomes can 
remain in this state in the nucleus of neurons for the lifetime of the host.  Alterations in the host-
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virus interaction may cause “reactivation” of the viral infection from a quiescent state to a 
productive, lytic cycle of viral replication.  Expression of ICP0 and various types of stress can 
trigger reactivation (40, 117, 128, 129, 190, 282).  During latency, however, ICP0 is not 
expressed, and reactivation is thought to occur when stress stimuli derepress ICP0, promoting 
viral gene expression and lytic infection (87).  Productive infection results in a lytic cascade of 
viral gene expression and the production of mature virions which can then travel back down the 
nerve axon via anterograde transport and establish infection at mucocutaneous surfaces 
innervated by the infected neuron (55).  At least 76 of the total 84 HSV-1 genes are expressed 
during lytic infection (213).  Cell lysis and release of mature virions allows for spread of the 
virus.  Recurrent cutaneous infections occur due to reactivation of the virus from latency in 
neurons at different time points throughout the life of the individual.  
 
1.4.3.3. HSV Gene Expression 
If lytic infection occurs after HSV nuclear entry, viral genes are expressed in a tightly regulated 
temporal cascade in which three classes of viral genes are sequentially expressed:  immediate 
early (IE) or α, early (E) or β, and late (L) or γ (150, 151).  All viral genes are expressed as 
cellular RNA polymerase II transcription units utilizing the host cellular transcription machinery.  
Each class of genes differs with respect to its promoter structure, which decreases in complexity 
from IE to L genes (339).  Early promoters differ from IE promoters in that they lack the virus-
specific TAATGARAT sequences present in IE promoters.  Both E and IE promoters contain a 
TATA box and retain upstream cellular activating sequences, such as Sp1 and CCAAT boxes, 
that contribute to activation of these genes (86, 113).  L promoters contain a TATA box and are 
devoid of any essential upstream activating sequences (98).  Only two known elements 
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downstream from the TATA box are important for late gene expression, the initiator element 
(INR), which overlaps the transcriptional start site, and the downstream activating sequence 
(307).  These class-specific differences in promoter structure may be important in determining 
the ability to nucleate the assembly of stable preinitiation complexes at various phases of 
infection, in part mediating kinetic class-specific transcription (328, 359). 
The IE genes are the first viral genes expressed upon infection and possess the main 
regulatory activities of viral gene expression.  The resultant IE proteins are necessary for the 
subsequent expression of the E and L gene classes.  The E genes encode proteins involved in 
nucleotide metabolism and viral DNA replication.  HSV encodes its own DNA replication 
machinery.  The third class of viral gene expressed, the L genes, encode mainly structural 
components of the virus particle.   
The temporal nature of the cascade of events during HSV gene expression with lytic 
infection is well defined (150, 151).  IE gene expression is detectable within 30 minutes of 
infection, with maximal protein accumulation occurring between 2-4 hours post-infection (hpi).  
The E genes reach peak rates of synthesis between 5-7 hpi.  Viral DNA replication is detectable 
as early as 3 hpi and continues through 12-15 hpi.  L gene expression can be detected soon after 
initiation of viral DNA replication and peak levels of L proteins occur after 8 hpi.  During lytic 
infection, the eclipse period is 5 hours and progeny virus is released throughout the remainder of 
the replication cycle, which is approximately 18 hours. 
 
1.4.3.4. HSV Immediate-Early Proteins 
There are five HSV IE proteins expressed by designated infected cell polypeptide 0 (ICP0), 
ICP4, ICP22, ICP27, and ICP47.  The IE genes are expressed in the absence of de novo viral 
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protein synthesis.  During HSV lytic infection, the viral transactivator, VP16, enters the cell as a 
component of the virion tegument (318).  VP16 complexes with host cellular factors, Oct-1 and 
host cell factor (HCF), bind TAATGARRAT motifs present in all HSV-1 immediate early (IE) 
promoters (99, 179, 180, 248, 266, 319).  This complex recruits transcriptional activators and 
RNA polymerase II to IE promoters, which subsequently express the five infected cell 
polypeptides (ICP).  In addition to a TATA box and TAATGARAT elements, sites exist for 
several cellular cis-acting factors such as Sp1 and others that contribute to enhanced transcription 
or transcription in the absence of VP16 (112). 
Gene expression during lytic infection progresses in a regulated cascade in which the five 
IE gene products, ICP0, ICP4, ICP22, ICP27, and ICP47, are the first viral proteins synthesized 
upon infection, with the exception of ICP47, encode the primary regulatory functions of the virus 
necessary for the efficient and timely expression of early and late gene expression (53, 151, 258). 
Of the five IE proteins, only ICP4 and ICP27 are absolutely essential for productive viral 
replication (69, 76, 212).  The remaining IE proteins ICP0, ICP22, and ICP47 fulfill accessory 
roles to optimize viral replication.  
ICP47 is the only IE protein that does not function directly in regulating viral gene 
expression.  The role of ICP47 during infection is in the down-modulation of the host immune 
response.  ICP47 functions to limit the presentation of antigens via the major histocompatibility 
(MHC) class I pathway (100, 355).  This occurs as a consequence of interaction between ICP47 
and the transporter associated with antigen processing (TAP).  TAP passes peptides to the 
endoplasmic reticulum (ER) lumen for assembly onto MHC-1 and the interaction with ICP47 
impedes this function.  As a result, MHC Class I molecules are retained in the endoplasmic 
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reticulum/cis-Golgi apparatus within hours after infection.  The infected cell is thus prevented 
from displaying Class I antigens and is preserved from lysis by CD8+ T lymphocytes. 
ICP22 is thought to function during infection by facilitating L gene expression, thereby 
promoting the switch from E to L gene expression.  ICP22 enables full expression of a subset of 
L viral genes by causing cdc2 cyclin-dependent kinase activity to survive the degradation of its 
physiologic partners cyclins A and B, by an aberrant partnership with the UL42 DNA polymerase 
processivity factor (2, 3, 6).  Optimal transcription of late genes requires binding and 
posttranslational modification of topoisomerase IIα by ICP22 and cdc (5).  ICP22 is not essential 
for virus replication, and phenotypic effects on virus replication and gene expression are highly 
cell-type dependent (290).  ICP22 has been shown to affect the stability of the ICP0 transcript as 
well as splice site usage during processing of ICP0 mRNA (43).  ICP22 is associated with the 
aberrant phosphorylation state of the C-terminal domain of cellular RNA Pol II in HSV infected 
cells (273), and is thought that this phosphorylation pattern affects the targeting and activity of 
the RNA Pol II transcription complex on viral promoters.   
ICP27 is required for viral replication, and appears to be multifunctional during infection 
(285).  ICP27 is generally associated with activating E and L gene expression (212).  In addition 
to this transactivation function, ICP27 is also associated with the repression of gene expression 
(218, 273, 291) which likely aids in the orderly transition from IE, E, and L gene expression.  
ICP27 exerts additional regulatory influences post-transcriptionally by modulating mRNA 
processing of both viral and cellular transcripts (132, 217, 289) and with poly-A site useage 
(216).  ICP27 has been shown to block RNA splicing but not transport of unspliced RNA early in 
infection (287).  ICP27 also has been shown to affect the export of certain classes of mRNA 
(260, 303), as well as the shut-off of host protein synthesis (131, 289).  ICP27 is active as a 
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chaperone of newly made viral mRNA across the nuclear membranes at late times after 
infection.  ICP27 has been demonstrated to affect the post-transcriptional processing of ICP0 
(131, 132) and the post-translational modification of ICP4 (218, 273) which may play a role in 
ICP27 modulation of E and L gene expression. 
ICP4 is the major regulatory protein of the virus and is absolutely required for the 
transition of viral gene transcription from the IE to the E phase due to its role as a transcriptional 
activator of early and late genes (76, 265, 335).  ICP4 is located in the US repeat sequences and is 
thus present in two copies in the viral genome.  It can function as a repressor (70, 120, 221) or 
activator (70, 88, 113) of transcription by forming multiple contacts with basal transcription 
factors (42, 120, 300, 358).  Transcriptional regulation by ICP4 involves complex interactions 
with the cellular transcription machinery (19, 56).  One such interaction involves the ICP4 C-
terminal activation domain which interacts with RNA Pol II general transcription factor, TFIID, 
via its TATA binding protein (TBP) associated factor 250 (TAF250) subunit (42).  Although 
ICP4 contains a DNA binding region that is essential to activation (71), no specific ICP4 binding 
sites have been identified on early and late promoters that are responsible for activation (86).  
Deletion of ICP4 eliminates expression of early and late genes (69).  However, certain mutations 
in ICP4 that have no effect on early gene transcription do not allow late gene expression, 
suggesting ICP4 may act differently on early and late promoters (71). 
ICP0 has been described as a promiscuous transactivator of both viral and cellular 
promoters in transient assays.  ICP0 activates a specific subset of cellular genes, including p53-
responsive genes that it activates independently of p53 (143).  ICP0 is the only viral protein 
capable of transactivating all three classes of viral genes (47).  ICP0 activates transcription of 
viral genes in synergy with or independent of ICP4 (88, 111, 160).  ICP0 has been shown to 
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interact with ICP4, and this interaction is believed to mediate cooperative activation of gene 
expression, as it maps to a region of ICP0 that contains the domain involved in synergy with 
ICP4 (352).  HSV mutants deficient for ICP0 function are severely growth impaired and do not 
efficiently reactivate from latency in animal models (40, 52, 117).  The role of ICP0 during 
infection is generally considered to be in promoting lytic cycle events and inhibiting latency.  
Recently, ICP0 has been shown to inhibit circularization of the HSV-1 genome and promote lytic 
infection (156, 288).  ICP0 does not bind DNA, but activates gene expression at the level of 
mRNA synthesis by increasing the rate of transcription (162, 286).  ICP0 interacts with host 
cellular proteins and pathways by complex interactions.  In fact, ICP0 targets many cellular 
proteins for destruction, including nuclear structures known as ND10, which contain the 
promyelocytic protein (PML) and Sp100 (46, 93).  Other proteins targeted for destruction by 
ICP0 include the catalytic subunit of the DNA-dependent protein kinase (DNA-PKCS) (189, 255) 
and centromeric proteins C and A (91, 197).  ICP0 has been shown to function as an E3 ubiquitin 
ligase (28, 87) conjugating ubiquitin onto proteins, in a RING finger-dependent manner, and 
targeting them for degradation by the ubiquitin-dependent proteosome degradation pathway (93).   
 
1.4.3.5. HSV DNA Replication and Recombination 
Replication of HSV occurs within the nucleus of the infected cell.  HSV encodes over 80 gene 
products that contribute to viral replication in either cultured cells or animal hosts (280).  Due to 
the limited size of the HSV-1 genome, the virus cannot code for every function required for its 
propagation.  HSV-1 must rely upon factors supplied by the host cell for replication.  For 
example, HSV exclusively uses the host cell RNA polymerase II for transcription of viral genes 
(57). 
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Viral DNA synthesis takes place within globular domains in called replication 
compartments (269), which contain the seven essential viral DNA replication proteins:  the 
origin-binding protein (UL9), the single-stranded-DNA-binding protein (UL29 or ICP8), the 
helicase-primase heterotrimer (UL5/UL8/UL52), the viral polymerase (UL30), and its 
processivity factor (UL42)(342).  Other viral proteins that are found in the replication centers 
include ICP4, ICP27, and the major capsid protein VP5 (67, 172, 195, 261).  Cellular proteins 
that have been shown to localize within replication compartments include p53, Rb, and the 
DNA-binding replication protein A (RPA) (345).  Recently, various cellular proteins involved in 
DNA recombination/repair have also been shown to localize within replication compartments 
such as DNA-PKCS, Ku86, BLM, Nbs1, PCNA, BRCA1, MSH2, Rad50, Rad51, and WRN (317, 
346).  
Initially, viral DNA replication was thought to occur via a rolling circle mechanism that 
generated head-to-tail concatamers of viral genomes (23, 158, 159).  HSV genome 
circularization was believed to be a prerequisite for viral DNA replication that involved 
recombination of the terminal repeats, resulting in a θ replication mode for the initial round of 
replication, providing the template for a rolling circle mode of replication (279, 299).   
Recently, our group has challenged the concept of HSV genome circularization as a 
requirement for viral DNA replication.  Jackson and DeLuca have shown that genome 
circularization does not occur in productive infection but instead may occur during the 
establishment of latency as a function of ICP0 expression (156, 288).  ICP0 appears to prevent 
the formation of circular HSV-1 DNA molecules.  HSV-1 mutants defective for ICP0 expression 
resulted in the predominance of circular HSV-1 genomes during infection.  The finding that 
ICP0 appears to prevent the formation of circular molecules may explain why replication of 
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HSV-1 is greatly reduced in HSV-1 mutants defective in ICP0 at low multiplicities of infection 
(283, 309).  Jackson and DeLuca have postulated that linear HSV molecules rather than circles 
might serve as the initial templates for HSV-1 replication.  Genome replication may proceed 
from the three origins of HSV-1 DNA replication, oriL and two copies of oriS, to produce highly 
branched structures that might then be resolved by recombination or during packaging of viral 
DNA.   
Several lines of evidence indicate that the process of HSV-1 DNA replication is linked to 
recombination.  For example, recombination is a frequent event within the HSV-1 genome as 
well as between infecting genomes and is stimulated on HSV-1 infection (78, 79).  Newly 
replicated DNA is larger than unit length and adopts a highly complex structure, the formation of 
which is presumed to require recombination (203).  Newly replicated DNA also undergoes 
genomic inversion (17).  Viral proteins may function to promote recombination and it is likely 
that recombination during HSV-1 infection also may involve cellular recombination pathways 
(243, 354). 
 
1.4.3.6. HSV Infection, ND10 Domains, and DNA Damage Response 
HSV DNA replication is closely associated with nuclear matrix-bound multiprotein domains 
called ND10 domains (also called promyelocytic leukemia [PML] nuclear bodies), which are 
defined and organized by the PML protein (11, 154, 210).  Upon entry into the nucleus, parental 
viral genomes are found adjacent to ND10 domains (210) early in infection, and the IE protein, 
ICP0, induces degradation of PML and the dispersal of ND10 domains and associated proteins 
(94, 209). 
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ND10 domains have been shown to contain host recombination/repair proteins (235) and 
participate in the cell’s response to DNA damage (41).  ND10 domains are redistributed in 
response to DNA damage (41), and it has been proposed that ND10 may store and release 
proteins in response to certain external insults such as viral infection and DNA damage (235).  
For example, the ND10-associated proteins PML, Mre11, γH2AX, Rad50, NBS1, RPA, and 
TopBP1 are redistributed to double-strand DNA repair foci induced by ionizing radiation (16, 
41, 351).  Recently, HSV infection has been shown to induce a cellular response to DNA damage 
with recruitment of recombination and repair proteins to HSV-1 DNA (193, 346).  Activation 
and exploitation of a cellular DNA damage response has been shown to aid viral replication in 
nonneuronal cells (193).  Activation of ATM, Chk2, 53BP1, and Nbs1 have been shown after 
HSV-1 infection.  ATM activation appears to be an early event that precedes signaling to other 
proteins and expression of ICP0.  In contrast to adenovirus infection, HSV-1 infection does not 
alter steady-state levels of Mre11/Rad50/Nbs1.  ATM, Nbs1, and Rad50 proteins have been 
shown to accumulate at sites of HSV-1 replication.  Lilley and Weitzman have suggested that 
when the DNA damage response is absent, HSV-1 replication is impaired (193).  In cell lines 
harboring mutations in Mre11 or ATM, viral yield was shown to be decreased.  The defect in 
HSV-1 growth in the absence of a DNA damage response is even more marked with infection by 
an ICP0-null virus.  In neuronal cells, HSV-1 infection is unable to elicit a DNA damage 
response which is consistent with prior reports that neurons are inefficient at DNA repair (246).  
Inability to mount a DNA damage response and viral replication compromise may contribute to 
the establishment of viral latency in neuronal cells. 
Recently, our group has suggested the ends of the HSV-1 linear genome could be treated 
as DNA double-strand breaks, which could be repaired as circular genomes (156).  The 
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expression of ICP0 early during lytic infection would inhibit the repair process by ND10 body 
disruption and degradation of the catalytic subunit of DNA-dependent protein kinase 
(DNAPKcs).  As a result, circularization of HSV-1 DNA would not proceed and replication of 
linear HSV-1 genomes can occur. 
 
1.4.3.7. HSV Assembly and Release 
The replication of HSV-1 does not produce genomic DNA molecules, but rather concatemers 
containing many head-to-tail copies of the viral genome.  Individual genomes are therefore 
liberated from the concatemers.  Cleavage of viral DNA at terminal repeat sequences into 
genome length segments can then be packaged into preformed capsids (220).  These particles, or 
nucleocapsids, are non-infectious and unstable until they acquire an envelope.  The mature 
nucleocapsid that is assembled within the nucleus initially acquires an envelope by budding 
through the inner nuclear membrane (100).  Upon fusion with the outer nuclear membrane, this 
membrane is lost as unenveloped nucleocapsids are released from the cytoplasm (220).  
Envelope glycoproteins are initially added in the first stage of the secretory pathway, the 
endoplasmic reticulum.  The final envelope is acquired upon budding of tegument-containing 
structures into a late compartment of the secretory pathway in the transgolgi network.  The viral 
particles then reach the cellular plasma membrane and are released into the extracellular space 
via cellular secretory and trafficking pathways in which the capsids may exchange envelope 
moieties with other cellular membrane bound compartments.  
 
1.4.4. ICP0  
ICP0 is required for both HSV lytic viral infection and efficient reactivation from latency in vitro 
and in vivo (40, 117, 128, 129, 190, 282).  ICP0 is a promiscuous transactivator shown to 
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enhance the expression of genes introduced into cells by infection or transfection (127).  ICP0 is 
critical for viral replication in cultured cells infected at low multiplicity, but is not essential in 
cells infected at high multiplicity (283, 290).  One copy of the ICP0 gene exists on each end of 
the UL sequence of the HSV-1 genome within the repeat sequences.  ICP0 is a 110 kDa (775 
amino acids in length) protein translated from a spliced mRNA containing three exons encoding 
19, 222, and 534 amino acids (127).  ICP0 is extensively posttranslationally processed (1).  It is 
phosphorylated by the viral protein kinase UL13 (249) and the cell cycle kinase cdc2 (6) and 
nucleotidylylated by casein kinase II (224).  Modifications of ICP0 are sequential and are 
associated with specific locations of the protein within cellular compartments (3).  Newly 
synthesized ICP0 accumulates initially at or near ND10 structures (209).  As the amount of ICP0 
increases, the protein spreads out and fills the nucleus.  Late in infection, after the onset of viral 
DNA synthesis, ICP0 is found in the cytoplasm (198).  ICP0 appears to shuttle between the 
nucleus and cytoplasm and may linger rather than reside in the cytoplasm at late times after 
infection (127). 
ICP0 participates in many cellular processes that lead to transactivation of gene 
expression indirectly even though it does not bind DNA (90, 96).  Activation of gene expression 
by ICP0 is considered to occur at the level of mRNA synthesis (162, 286).  Mutational analysis 
has demonstrated the importance of an N-terminal C3HC4 (RING finger) motif in ICP0 activity, 
and such domains are thought to mediate protein-protein interactions (85, 89, 95, 102, 103). 
 
1.4.4.1. ICP0 Conquest of Host Cell Metabolism 
ICP0 is a multifunctional protein whose multitude of interactions with cellular metabolic 
functions translates into dysregulation of cell metabolism and cytotoxic effects.  Infection with 
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HSV-1 has been linked to inhibition of cellular DNA synthesis associated with cell cycle arrest 
(66).  ICP0 has been shown to cause cell cycle arrest at both G1/S and G2/M checkpoints (143).  
ICP0 expression in cells results in the induction of p53-responsive genes p21, gadd45, and 
MDM2.  ICP0 has also been shown to induce these genes in the absence of cellular p53.  The 
histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), is able to reproduce many of the 
effects of ICP0 on viral and cellular gene expression (143).  Low level expression of ICP0 
(1,000-fold lower relative to the level of expression from HSV-1 vectors) from an adenovirus 
construct, has been shown to not affect cellular division, perturb cellular metabolism, or cell 
survival (144).  
ICP0 has been shown to function as an E3 ubiquitin ligase (28, 87) conjugating ubiquitin 
onto proteins, in a RING finger-dependent manner, and targeting them for degradation by the 
ubiquitin-dependent proteosome degradation pathway (93).  As a viral protein that stimulates 
viral gene expression by targeting cellular proteins for degradation, ICP0 is thought to target 
cellular proteins that repress viral gene expression (87).  ICP0 has been shown to target proteins, 
such as PML and Sp100, that are major constituents of ND10 bodies (93).  ND10 bodies are 
discrete nuclear foci where HSV-1 genomes may localize early during infection (210).  Recent 
studies have suggested that these foci are sites of DNA double-strand break (DSB) repair and 
inhibition of HSV genome circularization by ICP0 (41, 156).  Other proteins targeted for 
degradation include centromere proteins, CENP A (197) and CENP-C (92, 196), the E2 
ubiquitin-conjugating enzyme cdc34 (UbcH3) (127), and the catalytic subunit of DNA-
dependent protein kinase (DNA-PKcs) (189, 255). 
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1.4.4.2. ICP0 Degradation of DNA-PKCS 
HSV-1 infection causes the active degradation of DNA-PKCS, a major player in the NHEJ 
pathway of DSB DNA repair.  This process is reliant on the expression of the IE protein, ICP0 
(189, 255).  The extent of DNA-PKcs degradation is cell-type specific and it has been shown that 
degradation occurs between 2 and 6 hours post-infection by HSV-1.  The RING finger domain of 
ICP0 is required for DNA-PKcs degradation (255).  The proteosome pathway is responsible for 
the virus-induced degradation of DNA-PKcs., and in the presence of a proteasome inhibitor, 
degradation of DNA-PKcs is inhibited.  ICP0 does not directly affect the enzyme activity of the 
DNA-PK and does not physically interact with DNA-PKcs.  Parkinson et al., have shown that 
degradation of DNA-PKcs does not appear to be spatially regulated like the PML protein in 
ND10 bodies (255).  At the time DNA-PKCS degradation is observed, ICP0 is not present in a 
punctate, ND10-related pattern but is diffuse throughout the nucleus.   
 
1.4.5. HSV-1 and NHEJ 
Evidence suggests the cellular NHEJ pathway inhibits HSV replication.  Disruption of this 
pathway has been shown to enhance viral replication (255, 317).  Parkinson et al., have shown 
that ICP0-induced degradation of DNA-PKCS and loss in DNA-PK activity appears to be 
beneficial to HSV-1 infection, as virus replication is more efficient in cells lacking DNA-PKCS, 
especially at low multiplicities of infection (255).  Taylor and Knipe have recently shown in cells 
whose NHEJ pathway is disrupted, HSV-1 growth is increased (317).  Viral yields were shown 
to increase 30- to 50 fold in murine embryonic fibroblasts deficient in Ku70.  
 
1.4.6. HSV-1 Replication-Defective Mutants 
Recombinant HSV-1 mutants have been constructed with deletions in IE genes to reduce cell 
toxicity, permit transgene expression, and inhibit viral replication (284, 349).  In ICP4 mutant 
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backgrounds, expression of viral early and late genes is dramatically reduced, inhibiting viral 
replication (69).  This has led to the consideration of such backgrounds as starting points for the 
construction of replication incompetent HSV-1 gene transfer vehicles.  Despite the limited 
expression of the HSV genome in ICP4 mutant backgrounds, such mutants are very toxic to 
cells.  This is due to the overexpression of the remaining IE proteins in the absence of ICP4 (69).  
Improved cell survival has been shown by further reduction in IE gene expression after deletion 
of other IE genes in the HSV-1 genome (161, 284, 286).  Both ICP0 and ICP22 contribute to 
toxicity, as demonstrated by the improved survival of infected cells when either ICP0 or ICP22 is 
deleted in viruses already deficient in ICP4 and ICP27 expression (286, 349).  At high 
multiplicities of infection (MOI), both of these triple mutants remain toxic to cells.  Elimination 
of all IE gene and protein expression (ICP 0, 4, 22, 27, and 47) results in a virus that is nontoxic 
at high MOI and is capable of long-term persistence in nonneuronal cells.   
 The degree of transgene expression in different IE-deficient HSV mutants has been 
shown to be dependent on the ICP0 protein (284).  Green fluorescent protein (GFP) transgene 
expression has been shown to be abundant in cells infected with a recombinant HSV-1 virus that 
expresses only ICP0.  In the absence of all of the HSV IE proteins, the level of GFP transgene 
expression is low.  Transgene expression of cells infected by a complete IE-deficient virus can be 
stimulated by ICP0. 
 
1.4.6.1. d106 and d109 (Fig. 3) 
The mutant virus, d106, is defective in the expression of all of the IE viral genes (ICP4- ICP22- 
ICP27- ICP47-) except that which encodes ICP0 (284).  The d106 virus overexpresses ICP0 
relative to wild-type HSV-1 (81).  The mutant virus d109 is an isogenic mutant of d106 and does 
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not express any of the IE viral genes necessary for HSV-1 genome expression.  This virus, d109, 
is non-toxic to cells at high multiplicities of infection (MOI) and can persist in a repressed, 
quiescent state in cultured nonneuronal cells.  Low levels of ICP0 can effectively activate gene 
expression in trans and promote persistent transgene expression in cis from otherwise silent 
promoters contained on persisting d109 viral genomes (144).  Construction of the viruses, d106 
and d109, proceeded in a series of steps that generated and utilized a set of mutants defective in 
sets of IE genes (284).  Deletion mutations have been placed in the coding sequences of 
ICP0/4/27 while ICP22/47 have a TAATGARAAT deletion introduced into their promoters.  In 
place of the deletion of ICP27, a GFP gene under the control of the human cytomegalovirus 
(HCMV) IE promoter was inserted.   
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Figure 3.  Structures of the isogenic HSV-1 mutants, d106 and d109.  A.  The HSV-1 viral genome is represented 
with the unique long (UL ) and short (US) regions bounded by terminal and internal repeats (white boxes).  The 
genomic locations and directions of transcription of the IE genes are indicated (arrowheads).  Expanded map of the 
right end of the d109 genome, showing coding sequences of the IE genes (solid arrows) and the deletion mutations 
(white bars) in ICP4 (d120), ICP0 (0Δ), and the ICP22/47 promoter (TGTΔ).  The transgene cassette containing the 
GFP reporter gene under the control of the HCMV IE promoter substituted into the deletion in ICP27 is represented 
by a shaded bar, with the arrow inside indicating the direction of transcription.  The relevant restriction sites are as 
follows:  H, HpaI; P, PstI; S, SacI; B, BamHI; and N, NcoI.  B.  The TAATGARAT deletion, TGTΔ (bracketed), 
introduced into the promoter regions of ICP22/47.  The positions of the TAATGARAT elements (open arrows), 
binding sites for the transcriptions factor Sp1 (arrowheads), TATA boxes (open squares), and oriS (open circle) are 
shown relative to the transcription start sites of ICP4 and ICP22/47 promoter (TGTΔ).  C.  Genomic structures of 
d106 and d109.  The deletion mutations in ICP4, ICP0, and the ICP22/47 promoter present in both virus mutant 
strains are indicated by the shaded bars inside the white boxes representing the repeat sequences.  The GFP 
substitution in ICP27 is also shown (inverted triangles).  The mutant designations are indicated on the right along 
with a list of the IE proteins not synthesized by the viruses in the absence of complementation.  (Figures adapted 
with permission from Samaniego et al. J Virol 72(14), p 3310, 1998) 
 
1.4.7. HSV-1 Replication-Conditional (Oncolytic) Viruses 
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Replication-conditional HSV-1 viruses, also known as oncolytic viruses, have been genetically 
engineered to replicate and grow in tumor cells and cause their demise (194). A number of 
different genetically engineered oncolytic viruses have been constructed with deletions or 
mutations in one or more HSV genes (γ134.5, UL39, tk, and UTPase) in an effort to decrease the 
toxicity of HSV to the CNS and provide a condition for viral replication only in replicating cells 
that can provide cellular homologues (49, 51, 54, 152, 175, 208, 222, 267).   
The first study of a genetically-engineered virus used as an HSV-1 oncolytic agent was a 
tk deletion HSV-1 mutant, dlsptk (208).  This virus was previously constructed and determined 
to lack neurovirulence (54).  In a mouse glioma model, dlsptk demonstrated antiglioma effects 
with tumor growth inhibition and increases in animal median survival.  Shortcomings of the 
dlsptk virus included acyclovir resistance, due to the tk deletion, and long-term surviving 
animals had evidence of low-grade encephalitis.  Another HSV-1 oncolytic virus was generated 
containing a 1 kb deletion in both copies of the diploid viral gene, γ134.5, located in the terminal 
α repeats of the UL segment (49).  R3616 was found to be aneurovirulent at the highest doses 
obtainable after intracerebral inoculation in susceptible mouse species (51).  HSV1716 was also 
developed which had both copies of the RL1 gene deleted encoding the protein ICP34.5 (271).  
The γ134.5 gene has been determined to encode for the neurovirulence elicited by HSV infection, 
and has been termed the neurovirulence factor.  The carboxy terminus of this factor is 
responsible for evading a stereotypical antiviral response of the host cell by the shutdown of all 
protein synthesis in the cell.  While this results in cell death, the purpose of the response is to 
prevent further spread of viral infection to other cells in the host organism (50).  
Other HSV-1 oncolytic viruses have been developed based on 1 kb deletions of both 
copies of γ134.5 (222, 254).  Using R3616 as a parent virus, G207 was developed after creation 
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of an additional mutation to the virus by introduction of a lacZ reporter gene in the UL39 gene 
locus (222).  UL39 encodes for the large unit of HSV’s ribonucleotide reductase gene, ICP6, 
which is necessary for replication of the viral DNA in non-replicating cells.   
Phase I clinical studies in humans with malignant gliomas have demonstrated modest 
antitumor effect with the HSV-1 oncolytic viruses G207 and 1716 (134, 206, 271).  Safety has 
been established when viruses are injected into the brains of patients with malignant gliomas.  
Delivery of HSV-1 vectors in all clinical trials has been by multiple stereotactic intratumoral or 
peritumoral injections after surgical resection (134, 206).  Such techniques are problematic as 
viral delivery is unable to produce widespread and uniform distribution within tumors. 
 
1.4.7.1. Oncolytic HSV-1 and Ionizing Radiation 
Advani et al., have shown the conditionally-replicative HSV-1 mutant, R3616, has greater 
oncolytic effects and increased replication when exposed to IR (4).  In their study, human U87-
MG xenografts in mice underwent significantly greater reduction in tumor volume or total 
regression when tumors were inoculated with the R3616 mutant and irradiated.   Increased 
spread of the virus was seen with in-situ hybridization with DNA probes to the virus.  Other 
studies have confirmed the enhanced tumoricidal effect of HSV when combined with IR (30, 
205).   
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2. STATEMENT OF THE PROBLEM 
 
Despite the use of conventional therapeutic modalities such as surgery, chemotherapy, and IR, 
the prognosis in patients with GBM remains poor.  To improve this dismal prognosis, novel 
treatment approaches are required which attack the molecular and biological features of 
malignant gliomas.  Since these tumors rarely metastasize away from the nervous system and the 
majority recur in a local fashion, local tumor control must be achieved to significantly extend the 
survival of patients with GBM.  Enhancement of the effects of IR, the primary adjuvant 
treatment for GBM, may serve this purpose.   
 DNA DSBs are known to occur with IR exposure of cells (168).  DNA double-strand 
breaks (DSBs) are the most critical form of DNA damage that may result in loss or 
rearrangement of genomic material and thereby lead to mutations, genomic instability, cancer 
development, or cell death (74, 146, 259, 347).  DNA DSBs activate an extensive array of 
responses that lead to damage repair and continuation of cellular life (157). 
HSV-1 is a large, neurotropic DNA virus that affects many aspects of host cell 
metabolism during infection.  During lytic cell infection, HSV-1 has been shown to induce a host 
DNA damage response with recruitment of recombination and repair proteins to HSV-1 genomes 
present in the nucleus (156, 193, 346).  Activation and exploitation of a cellular DNA damage 
response has been shown to aid viral replication (193).   
HSV-1 DNA replication is closely associated with ND10 domains, which are defined and 
organized by the PML protein (11, 154, 210).  ND10 domains have been shown to contain host 
recombination/repair proteins (235) and participate in the cell’s response to DNA damage (41).  
ND10 domains are redistributed in response to DNA damage (41), and it has been proposed that 
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ND10 may store and release proteins in response to certain external insults such as viral infection 
and DNA damage (235).  For example, the ND10-associated proteins PML, Mre11, γH2AX, 
Rad50, NBS1, RPA, and TopBP1 are redistributed to DNA DSB repair foci induced by IR (16, 
41, 351).  The phosphorylated form of the NHEJ DNA repair protein, DNA-PKCS, has also been 
shown to localize to sites of DNA DSBs (44).  
Upon entry into the nucleus, parental HSV-1 genomes are linear in structure and are found 
adjacent to ND10 domains (156, 210).  The ends of the HSV-1 linear genome may be treated as 
cellular DNA DSBs, and repaired by NHEJ, forming circular genomes that are associated with 
viral latency (156).  The expression of the IE protein, ICP0, during early lytic infection can 
inhibit the DNA repair process by ND10 body disruption and degradation of DNAPKcs (94, 189, 
209, 255).  As a result, circularization of HSV-1 DNA cannot occur and replication of linear 
HSV-1 genomes can proceed. 
The isolation of HSV-1, deleted for all IE genes except ICP0, can be used to study the 
effect of ICP0 on cellular DNA repair and survival after IR exposure and viral infection.  The 
HSV-1 mutant, d106, is essentially restricted to the expression of ICP0 and the transgene, GFP 
(284).  The d106 virus may be evaluated as a potential viral vector for delivery to the brain and 
ultimate treatment of GBM tumors by ICP0 DNA repair inhibition after IR. 
The aims of this study are to identify the ICP0 protein as a potential candidate for DNA 
DSB repair inhibition and radiosensitivity enhancement of experimental GBM.  Specifically, the 
aims are:  (1)  To determine the effect of HSV-1 infection and IR, on human GBM cell 
survival and proliferation in vitro;  (2)  To determine whether the degradation of DNA-PKcs 
by ICP0 occurs after HSV-1 infection and contributes to altered DNA DSB repair in GBM 
cells in vitro;  (3)  To determine whether CED is an optimal method of HSV-1 delivery to 
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the brain in a mouse model;  (4)  To determine whether the HSV-1 mutant, d106, enhances 
the radiosensitivity of mouse intracranial human GBM xenografts after CED. 
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3. INHIBITION OF DNA REPAIR BY A HERPES SIMPLEX VIRUS VECTOR 
ENHANCES THE RADIOSENSITIVITY OF HUMAN GLIOBLASTOMA CELLS 
 
A modified version of the data presented in Chapter 3 appeared in “Inhibition of DNA repair by 
a herpes simplex virus vector enhances the radiosensitivity of human glioblastoma cells,” Costas 
G. Hadjipanayis and Neal A. DeLuca, Cancer Research, 2005, volume 65 (12), pages 5310-
5316, copyright  2005, American Association of Cancer Research.  All rights reserved. 
 
3.1. Abstract 
Expression of the herpes simplex virus (HSV) protein, ICP0, from the viral genome, rendered 
two radioresistant human glioblastoma multiforme (GBM) cell lines more sensitive to the effects 
of ionizing radiation (IR).  Using the MTT and clonogenic survival assays, U87-MG and T98 
cell survival was more greatly decreased as a function of IR dose when ICP0 was preexpressed 
in cells compared to when ICP0 was not expressed.  Consistent with previous results, we found 
that the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) was degraded as a 
function of ICP0 in both cell types.  This most likely resulted in the inhibition of DNA repair as 
inferred by the persistence of γH2AX foci, or DNA double-strand breaks (DSBs).  Enhanced 
apoptosis was also found to occur following irradiation of U87-MG cells preinfected with the 
ICP0-producing HSV-1 mutant, d106.  Our results suggest that expression of ICP0 in human 
GBM cells inhibits the repair of DNA DSBs after IR treatment, decreasing the survival of these 
cells in part by induction of apoptosis.  
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3.2. Introduction 
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults 
(64).  Despite the use of conventional therapeutic modalities such as surgery, chemotherapy, and 
ionizing radiation (IR) treatment, the prognosis in patients is poor.  Radiation therapy remains 
the sole agent that increases the survival of patients with GBM but provides modest benefit 
(191).  Both adult primary (de novo) and secondary GBMs are remarkably resistant to IR 
treatment.  The limited efficacy of radiation treatment is believed to arise from the poor apoptotic 
response to IR by the tumor cells (167, 353, 356).  New therapeutic strategies need to be 
developed for improved long-term management of these tumors.  Enhancement of the effects of 
IR, the primary adjuvant treatment for GBM, may increase patient survival and quality of life.  
DNA DSBs are known to occur with IR exposure of cells (168).  One repaired DSB can 
be sufficient to kill a cell if it inactivates an essential gene or triggers apoptosis (274).  The repair 
of DSBs is performed by two pathways in mammalian cells, nonhomologous end-joining 
(NHEJ) and homologous recombination (HR).  The serine/threonine kinase, DNA-dependent 
protein kinase (DNA-PK), is an important component of NHEJ, consisting of a large catalytic 
subunit (DNA-PKcs) and a Ku heterodimer (Ku70 and Ku80 subunits).  In response to IR, Ku-
dependent phosphorylation of DNA-PKcs is required for the repair of DSBs by NHEJ.  DNA-
PKcs contributes to the repair of DSBs by assembling the broken ends of DNA molecules and 
serves as a molecular scaffold for recruiting DNA repair factors to DNA DSBs (10, 118, 183).   
Herpes simplex virus (HSV) is a large, neurotropic DNA virus that affects many aspects 
of host cell metabolism during infection.  The HSV-1 immediate early (IE) protein, ICP0, has 
been found to induce the degradation of the catalytic subunit of DNA-dependent protein kinase 
(DNA-PKcs) by the ubiquitin-dependent proteosome degradation pathway (189, 255).  The extent 
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of DNA-PKcs degradation is cell-type specific and it has been shown that HSV replication is 
increased in cells lacking DNA-PKcs (255).  Therefore, HSV infection may affect NHEJ.  
ICP0 is a promiscuous transactivator shown to enhance the expression of genes 
introduced into cells by infection or transfection (127).  ICP0 is critical for viral replication in 
cultured cells infected at low multiplicity, but is not essential in cells infected at high multiplicity 
(283).  Recently, ICP0 has been shown to be an E3 ubiquitin ligase (28) and has been proposed 
to promote lytic infections by destabilizing cellular proteins that inhibit the lytic viral life cycle.  
ICP0 is required for both lytic HSV viral infection and efficient reactivation from latency in vitro 
and in vivo (129).  In addition to DNA-PKcs degradation, ICP0 has been shown to induce the 
degradation of proteins associated with nuclear domain 10 (ND10) bodies in a RING finger-
dependent manner (93).  ND10 bodies are discrete nuclear foci where HSV-1 genomes may 
localize early during infection (210).  Recent studies have suggested that these foci are sites of 
DNA DSB repair and inhibition of HSV genome circularization by ICP0 (41, 156).   
Replication-defective mutant HSV-1 viruses were used to study the effect of ICP0 on DNA 
repair after IR in human GBM cells.  The mutant virus d106, is defective in the expression of all 
of the IE viral genes except that which encodes ICP0 (284).  The mutant virus d109 is an 
isogenic mutant of d106 and does not express any of the IE viral genes necessary for HSV-1 
genome expression.  Both of these mutant viruses were used to infect human GBM cells prior to 
irradiation to determine the effect of ICP0 on cell survival, proliferation, DNA-PKcs protein 
levels, DNA DSB repair, and apoptosis. 
 
3.3. Material and Methods 
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3.3.1. Cells and Viruses 
The human GBM cell lines T98 and U87-MG were obtained from the American Type Culture 
Collection (ATCC) and maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with sodium pyruvate, non-essential amino acids, antibiotics, and 10% fetal 
bovine serum (FBS) (Life Technologies, Inc., Gaithersburg, MD).  The HSV-1 IE mutant 
viruses, d106 and d109, are derived from the wild-type strain KOS and have been previously 
described (284).  Each mutant was grown and assayed for infectivity (PFU/ml) in the appropriate 
complementing cell lines (F06 and E11) as previously described (284).  AdS.11E4(ICP0), an 
adenovirus vector that expresses ICP0, and AdS.11D, the empty adenoviral vector, were 
provided by Douglas Brough (GenVec, Gaithersburg, MD) and have been described (144). 
 
3.3.2. HSV-1/Adenovirus Infection, IR, and Cell Survival/Proliferation 
Tumor cells were seeded in triplicate at 2 x 103 cells/well (0.1 ml) in 96-well flat-bottomed 
plates and incubated overnight at 37° C.  Confluent monolayers of T98 and U87-MG cells were 
infected with the HSV-1 viruses, d106 or d109, at an MOI of 10 for 24 hours prior to irradiation.  
U87-MG cells were also infected with 104 particles/cell with the adenoviruses AdS.11E4(ICP0) 
or AdS.11D.  IR treatment was delivered at room temperature in a 137Cs irradiator 
(Gammacell40, Atomic Energy of Canada Limited, Ontario, Canada) at a dose rate of .87 
Gy/min.  Cells were subsequently returned to the incubator. 
 To assess cell survival and proliferation after viral infection and IR treatment, an MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cell proliferation assay (ATCC, 
Bethesda, MD) (231) was performed at 0, 2, 4, and 6 days after cell irradiation.  MTT reagent 
was added (.02 ml) to each well and cells were placed in the incubator for 1 hour.  A solubilizing 
cell detergent (ATCC, Bethesda, MD) was added (0.1 ml) to the cells and the formazan reaction 
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product was measured with a microtiter plate reader (Dynateck, Alexandria, VA).  Absorbance 
values are presented as the mean of three wells per treatment ± the standard deviation (SD). 
 Clonogenic survival assays were performed on U87-MG cells after d106 infection and IR 
treatment.  Exponentially growing cells were seeded at a density of 105 cells/well in six well flat-
bottomed plates overnight.  Cells were either mock infected or infected with d106 at an MOI of 
10 PFU/cell for 24 hours.  Cells were irradiated at 10 Gy and placed in the incubator overnight.  
Trypsinized cells were serially diluted and plated in triplicate on six well plates.  Cells were left 
to grow colonies for 2 weeks with routine changing of serum-containing medium twice a week.  
Cells were fixed and stained with a crystal violet/formalin solution and colonies were counted.  
Cell survival was estimated from the number of colonies (defined as a cluster of >50 cells) 
formed and expressed as a fraction of the number of cells seeded multiplied by the plating 
efficiency (PE).  The PE was determined by the number of colonies formed in the mock infected 
group of cells that did not receive IR and expressed as a fraction of the number of cells seeded 
(PE= 0.9). 
 
3.3.3. Western Blot Analysis of DNA-PKcs and Cleaved Caspase-3 
For Western blot analysis of DNA-PKcs, U87-MG and T98 cells were infected with either d109 
or d106 and cell lysates were harvested at 6 and 24 hpi.  T98 and U87-MG cells were mock or 
d106-infected for 24 h and then irradiated (0 or 10 Gy) for Western blot analysis of cleaved 
caspase-3.  Cell lysates were collected at 48 h after irradiation.  Lysates were harvested into 
Laemmli buffer and loaded onto denaturing polyacrylamide gels using standard protocols.  Due 
to the large size of the protein (460 kDa), 8% bisacrylamide gels were used to resolve DNA-
PKcs.  The large fragment of cleaved caspase-3 (17/19 kDa) was resolved on 10-20% Tris-HCL 
gradient gels (Bio-Rad, Hercules, CA).  After electrophoresis, proteins were electrotransferred 
 52 
onto polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ) and probed 
for DNA-PKcs (mouse monoclonal at a dilution of 1:1000 in 5% nonfat dry milk/TBS-Tween 
solution; Upstate Biotechnology, Lake Placid, NY) and cleaved caspase-3 (rabbit monoclonal at 
a dilution of 1:1000 in 5% nonfat dry milk/TBS-Tween solution; Cell Signaling Technology, 
Beverly, MA).  This was followed by binding of peroxidase-conjugated goat antimouse/rabbit 
antibody and detection of proteins by enhanced chemiluminescence (Amersham Biosciences, 
Piscataway, NJ). 
 
3.3.4. Apoptosis 
A carboxyfluorescein poly-caspase detection kit (APO LOGIX, Cell Technology Inc., Mountain 
View, CA) was used to detect active caspases in cells undergoing apoptosis (302).  U87-MG 
cells were seeded in triplicate at a density of 105 cells/well in six well flat-bottomed plates 
overnight and were mock or d106 infected for 24 hours and then irradiated.  U87-MG cells were 
irradiated with 0, 5, 10, and 20 Gy.  Active caspases 1, 2, 3, 6, 8, 9, and 10 were detected with a 
carboxyfluorescein (FAM)-labeled peptide fluoromethyl ketone (FMK) caspase inhibitor 24 
hours after irradiation.  Quantitation of cells with active caspases undergoing apoptosis was 
performed with single color flow cytometry (Beckman-Coulter Epics XL, Fullerton, CA) after 
cell fixation (Fixative Solution, Cell Technology Inc., Mountain View, CA).  Data acquisition 
and analysis was performed with the EXPO32 ADC software (Beckman Coulter, Fullerton, CA). 
Staurosporine (A.G. Scientific, San Diego, CA), a potent apoptosis inducing agent, was used 
as a positive control for apoptosis in U87-MG cells for Western analysis of cleaved caspase-3 
levels.  Staurosporine was dissolved in anhydrous DMSO and diluted to a concentration of 0.01 
µM/L in medium prior to treatment of U87-MG cells for 2 hours. 
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3.3.5. Indirect Immunofluorescence for γH2AX and ICP0 
Confluent monolayers of U87-MG and T98 cells were grown on circular 18 mm coverslips.  
Cells were mock or d106-infected (MOI 10) for six hours and then irradiated (8 Gy).  At 2, 6, 
and 24 hours after IR treatment, cells were fixed and permeabilized in cold methanol (-20°C) for 
5 minutes.  Cells were then treated with deionized water for 20 minutes and then 10% phosphate-
buffered saline (PBS) for 15 minutes.  Cells were washed in 1% bovine-serum albumin (BSA) 
three times for 10 minutes each.  Anti-γH2AX (rabbit polyclonal at a dilution of 1:200 in PBS; 
Upstate Biotechnology, Lake Placid, NY) and anti-ICP0 (mouse monoclonal at a dilution of 
1:500 in PBS; Goodwin Institute for Cancer Research) antibodies were added and cells were 
incubated at room temperature for 1 hour.  Cells were washed in PBS five times for 10 minutes 
each before incubating in the dark with FITC-labeled secondary antibodies at a dilution of 1:500 
in PBS.  Cells were washed again in PBS six times 10 minutes each in the dark and coverslips 
were mounted with an antifade solution (Gelvatol, Simon C. Watkins Laboratory, University of 
Pittsburgh).  Slides were examined on a Nikon Diaphot 300 photomicroscope (Melville, NY).  
Images were captured by a SPOT RT camera (Diagnostic Instruments, Sterling Heights, MI) and 
imported into the SPOT version 3.5.9 for MacOS image analysis software package (Diagnostic 
Instruments, Sterling Heights, MI) running on a Macintosh G3 computer (Apple, Cupertino, 
CA).  Final image analysis was performed with Adobe Photoshop.  For each treatment condition, 
γH2AX foci were determined in at least 50 cells. 
 
3.3.6. Statistical Analysis 
Cell proliferation and viability data represent the average of three independent absorbance values 
on day 6 of the MTT assay.  Statistical proliferation and viability differences were assessed using 
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an unpaired two-sample Student t-test assuming equal variance.  A probability value less than 
0.05 was considered significant. 
 
3.4. Results 
 
3.4.1. Effect of ICP0 and IR on Human GBM Cell Survival and Proliferation:  MTT 
Assay 
To determine the effect of ICP0 on human GBM cell survival and proliferation after IR 
treatment, U87-MG and T98 cells were infected at an MOI of 10 PFU/cell with two replication-
defective HSV-1 viruses, d106 or d109, 24 h prior to single-dose irradiation (0, 5, 10, or 20 Gy).  
The MTT assay was performed at 0, 2, 4, and 6 days after cell irradiation (Fig. 1).  Both cell 
lines used are radioresistant and the U87-MG cell line contains wild-type p53 while T98 contains 
mutant p53 protein.  Both cell lines when irradiated, but not infected with virus, showed a dose-
dependent decrease in cell survival and proliferation in comparison to cells which received no IR 
(P< 0.005).  The U87-MG cell line appears more radioresistant than the T98 cell line in this 
study (Fig. 1).  Infection of U87-MG and T98 cells by the ICP0-producing virus, d106, followed 
by IR treatment, resulted in a dose-dependent decrease in cell proliferation and survival after 6 
days in comparison to cells receiving only IR (P< 0.005) (Fig. 1).  The greatest decrease in cell 
survival and proliferation occurred at the highest IR dose of 20 Gy (P< 0.005).  The largest 
decline in cell survival occurred between 2 and 4 days after IR treatment of U87-MG cells and 
infection with d106.  T98 cells showed a decline in cell survival immediately after IR.  Infection 
of both cell lines by the IE-deficient virus, d109, did not result in a dose-dependent decrease in 
cell proliferation and survival after IR treatment.  Cell proliferation occurred in both cell lines 
after d109 infection in the absence of irradiation consistent with the documented lack of toxicity 
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upon d109 infection (284).  Infection of both cell lines with d106 resulted in cell toxicity as 
proliferation and cell viability decreased soon after infection (P< 0.05) (143).  Cell toxicity with 
d106 infection was greatest in the T98 cell line (Fig. 1B).  
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Figure 4. Effect of HSV mutant viruses and escalating doses of ionizing radiation (IR) on U87-MG and T98 cell 
proliferation and survival using the MTT assay.  U87-MG or T98 cells were mock infected or infected with HSV 
mutant viruses, d106 or d109, at 10 PFU per cell.  The MTT assay was performed 0, 2, 4, 6 days after irradiation.  
A.  Effect of 5, 10, and 20 Gy IR exposure 24 hours postinfection (hpi) with mock, d106, and d109 infected U87-
MG cells.  B.  Effect of 5, 10, 20 Gy IR exposure 24 hpi with mock, d106, d109 infected T98 cells. ( Mock IR,  
d109 IR,  d106 IR,  Mock,  d109,  d106) 
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3.4.1.1. Adenovirus Expression of ICP0 
To confirm the effect of ICP0 on cell survival and proliferation in GBM cells after irradiation, 
U87-MG cells were infected with 104 particles/cell with two replication-defective adenoviruses, 
AdS.11E4(ICP0) or AdS.11D, 24 h prior to a single-dose of IR (20 Gy).  The MTT assay was 
performed at 0, 2, 4, and 6 days after irradiation.  AdS.11E4(ICP0) is an E1- E3- E4- adenovirus 
vector with ICP0 expression controlled from the endogenous adenoviral E4 promoter.  One-
thousand fold less ICP0 is expressed from this construct relative to the level of expression from 
d106 (144).  AdS.11D is an empty E1-E3-E4- adenovirus vector that does not express ICP0.  
U87-MG cells infected with the ICP0-producing adenovirus, AdS.11E4(ICP0), showed a 
decrease in cell survival and proliferation after irradiation in comparison to cells which were 
only irradiated (P< 0.005)(Fig. 2).  
 
Figure 5. Effect of empty adenovirus (AdS.11D) and ICP0-producing adenovirus [AdS.11E4(ICP0)] on U87-MG 
cell proliferation and viability after IR.  A.  U87-MG cells were mock infected or infected with AdS.11D or 
AdS.11E4(ICP0) at 10,000 particles/cell for 24 hours prior to 20 Gy IR exposure.  The MTT assay was performed 0, 
2, 4, 6 days after irradiation. (  Mock,  AdS.11D,  AdS.11E4(ICP0)) 
 
3.4.2. Effect of ICP0 and IR on Human GBM Cell Survival:  Clonogenic Survival Assay 
Clonogenic survival assays were performed to confirm the results of the MTT assay with d106 
infection of U87-MG cells and subsequent irradiation.  Cells were serially diluted and plated 
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after d106 infection and 10 Gy of IR treatment.  After two weeks of growth, cell survival was 
estimated from the number of colonies formed and expressed as a fraction of colonies resulting 
from uninfected, unirradiated cells (Fig. 3).  The survival fraction was lowest among cells that 
were infected by d106 and irradiated (0.001).  U87-MG cells that only received IR had an 
impaired ability to form colonies with a low survival fraction (0.01).  Cells that did not receive 
IR but were infected with d106 had a higher survival fraction (0.2).  These results support the 
data from the MTT assay showing an enhanced decrease in GBM cell survival with ICP0 
production and subsequent irradiation. 
 
Figure 6. Clonogenic survival performed on U87-MG cells after d106 infection and IR treatment plotted on a 
logarithmic scale.  Cells were mock or d106 infected at 10 PFU/cell for 24 hours and irradiated (0 or 10 Gy).  
Trypsinized cells were serially diluted and left to grow colonies for 2 weeks. Cell survival was estimated from the 
number of colonies (defined as cluster >50 cells) formed and expressed as a fraction of the number of colonies in the 
control (PE 0.9). 
 
3.4.3. Apoptosis as a Mode of GBM Cell Death with ICP0 Production and IR 
To determine whether apoptosis is a mode of GBM cell death with ICP0 production and IR, 
Western blot analysis was performed on U87-MG cells after d106 infection and irradiation (10 
Gy).  The blot was probed with an antibody specific to cleaved caspase-3.  Caspase-3, a key 
executioner of apoptosis, is activated by cleavage into two subunits (p17 and p12) (241).  Levels 
of cleaved caspase-3 (p17) were detected in U87-MG cells that were infected by d106 and 
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irradiated (Fig. 4A).  Lower levels of cleaved caspase-3 were found in cells that were d106 
infected but did not undergo irradiation.  Both groups of cells that were mock infected and did or 
did not receive IR had minimal detectable levels of cleaved caspase-3.   
 
Figure 7.  Apoptosis as a mode of GBM cell death with ICP0 production and IR.  A.  Cleaved caspase-3 levels after 
d106 infection and IR treatment.  U87-MG cells were mock (M) infected or infected with d106 at 10 PFU per cell 
for 24 h and then irradiated (0 or 10 Gy).   At 48 hours post-irradiation, cells were harvested into Laemmli buffer 
and samples were analyzed by Western blotting.  The blot was probed with rabbit monoclonal anti-cleaved caspase-
3 and mouse monoclonal anti-actin at a dilution of 1:1000.  Staurosporine (S), was used as a positive control for 
apoptosis in cells.  B.  Percentage of U87-MG cells undergoing apoptosis after d106 infection and IR treatment.  
U87-MG cells were mock infected or infected with d106 at 10 PFU per cell for 24 h and then irradiated (0, 5, 10, or 
20 Gy).  Carboxyfluorescein poly-caspase detection was performed by flow cytometry 24 h after irradiation to 
quantitate cells undergoing apoptosis. ( Mock,  d106) 
 
Carboxyfluorescein poly-caspase detection was performed with flow cytometry in order 
to quantify the number of U87-MG cells undergoing apoptosis after d106 infection and IR 
treatment (Fig. 4B).  Flow cytometry was performed 24 hours after cell irradiation.  Minimal 
apoptosis was detected in mock infected cells that did or did not undergo irradiation, confirming 
the results of our Western analysis of cleaved caspase-3 levels (Fig. 4A).  U87-MG cells that 
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were d106 infected and received subsequent IR treatment underwent apoptosis in greater 
numbers than d106 infected cells that were not irradiated.  The percentage of d106-infected cells 
undergoing apoptosis were very similar 24 h after irradiation at 5, 10, or 20 Gy (Fig. 4B).   
Our results confirm apoptosis as a mode of cell death with cell ICP0 production and 
irradiation.  At 24 h after irradiation, a large portion of U87-MG cells infected with d106 
undergo apoptosis.  Other modes of cell death such as necrosis or autophagy may also occur 
(353).  Our results support other studies showing irradiation alone causes a poor apoptotic 
response in GBM cells.  Most importantly, these results show enhanced GBM cell apoptosis with 
d106 infection and subsequent irradiation. 
 
3.4.4. ICP0 Degradation of DNA-PKcs in Human GBM Cells 
To determine whether degradation of DNA-PKcs by ICP0 occurs in human GBM cells, Western 
blot analysis was performed on U87-MG and T98 cells after d106 or d109 infection.  The blot 
was probed with anti-DNA-PKcs and degradation was found to occur between 6 and 24 hpi with 
d106 in U87-MG cells (Fig. 5).  Degradation of DNA-PKcs in T98 cells occurred at 6 hpi with 
d106 and complete degradation was found at 24 hpi (Fig. 5).  No degradation of DNA-PKcs 
occurred with d109 infection of the U87-MG or T98 cell lines. 
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Figure 8.  Effect of HSV mutant viruses on DNA-PKCS protein levels in U87-MG and T98 cells.  Cells were mock 
infected or infected with d106 or d109 as shown at 10 PFU per cell.  At 6 and 24 hpi, cells were harvested into 
Laemmli buffer and samples were analyzed by Western blotting.  The blot was probed with a mouse monoclonal 
anti- DNA-PKCS at a dilution of 1:1000. 
 
3.4.5. Persistent DNA DSBs with ICP0 Production and IR in Human GBM Cells 
To determine whether DNA DSB repair is inhibited by ICP0, indirect immunofluorescence was 
performed on U87-MG and T98 cells infected with d106 for 6 hours, irradiated, and incubated 
for 2, 6, and 24 hours (0 or 8 Gy)(Fig. 6).  Cells were labeled with antibodies to ICP0 and 
γH2AX, the phosphorylated form of a histone H2A variant (H2AX) found at sites of DNA DSBs 
(38, 277).  Phosphorylation of H2AX appears to play a critical role in the recruitment of repair or 
damage-signaling factors to sites of DNA damage in the nucleus (257).  The repair of DNA 
DSBs after IR correlates with the loss of γ-H2AX foci (233).  Prior reports have shown the loss 
of γ-H2AX foci in cells within 6 hours after irradiation (233). 
 U87-MG and T98 cells that were mock infected and did not receive IR had undetectable 
γ-H2AX foci, or DNA DSB (Fig. 6).  Mock-infected cells, which underwent IR treatment, had 
detectable γ-H2AX foci at 2 h post irradiation but reduced foci at 6 and 24 h.  The loss of γ-
H2AX foci at 6 and 24 h post-irradiation indicates the repair of dsDNA breaks.  Both T98 and  
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Figure 9.  Indirect immunofluorescence for γH2AX and ICP0 in U87-MG and T98 cells.  Cells were mock or d106 
infected for 6 h and then irradiated (0 or 8 Gy).  At 2, 6, and 24 h post-IR, cells were permanently fixed and labeled 
with anti-γH2AX (rabbit polyclonal) and anti-ICP0 (mouse monoclonal).  FITC-labeled secondary antibodies (red 
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for γH2AX and green for ICP0) were then added.  The presence of γH2AX foci, or DNA DSBs, are more numerous 
and persistent with d106 infection and IR treatment of cells at 24 h after irradiation.  A. U87-MG cells.  B. T98 cells. 
U87-MG cells infected with d106, which did not receive IR, had detectable γ-H2AX foci at 6 
and 24 h post irradiation.  These results suggest linear HSV-1 genomes present after infection 
may be treated as DNA DSB with formation of γ-H2AX foci (156, 279).  Abundant γ-H2AX 
foci, or DNA DSBs, were found in d106-infected cells at 2, 6, and 24 h after IR treatment (Fig. 
6).  Persistent γ-H2AX foci at 24 h suggests ICP0 inhibits DNA repair. 
 
3.5. Discussion 
Both primary and secondary GBMs are very resistant to the effects of IR.  GBM cells have a 
poor to absent apoptotic response to IR (167, 356) (353).  Glioma cells show an absence of either 
significant induction of bax or repression of bcl-2 and bcl-XL after irradiation (176, 298).  
Strategies reported to enhance apoptosis after irradiation of malignant glioma cells, include 
exogenous transfer of p53, APAF-1, and caspase 9 (116, 186, 297).  Radiation-induced apoptosis 
in most cell types other than glial cells has been shown to depend on the presence of wild-type 
p53 (200).  The presence or absence of wild-type p53 has not been shown to have a significant 
impact on the radiosensitivity of GBM cells (14, 125).  Recently, autophagic cell death has been 
introduced as a possible mechanism for GBM cell death after IR, characterized by the 
accumulation of acidophilic vesicular organelles (AVOs) in the cytoplasm (353).  Nevertheless, 
IR continues to be the primary adjuvant treatment modality for GBM patients as survival is 
modestly increased. 
 It has been firmly established that DNA-PKcs plays an important role in DNA end 
joining, especially DNA DSB repair after IR.  Prior reports have shown that inhibition or 
deficiency in DNA-PKcs leads to decreased DNA DSB repair and increased radiosensitivity, both 
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in vitro and in vivo (183, 188, 316, 325).  The repair of DNA DSBs after IR may account for the 
poor apoptotic response and ultimate radioresistance of malignant glioma cells.  Degradation of 
DNA-PKcs has been shown to occur after HSV-1 infection and is dependent on expression of the 
virus IE protein ICP0 (189).  We present evidence that an HSV-1 vector inhibits DNA DSB 
repair and enhances the radiosensitivity of human GBM cells possibly due to the degradation of 
DNA-PKcs.  Persistence of DNA DSBs with ICP0 production in GBM cells and irradiation is 
indicative of the disruption of the NHEJ repair pathway after degradation of DNA-PKcs by ICP0.  
The inhibition of DNA DSB repair by ICP0 may account for the enhanced apoptosis of GBM 
cells after ICP0 production and irradiation.  ICP0 may have many effects on cells.  It has also 
been shown that ICP0 induces cell cycle arrest in G1 and G2/M independently of p53 (143).  
Therefore, while ICP0 may inhibit DNA repair, it may also affect the survival of cells via other 
pathways. 
HSV-1 has been studied for use in the therapy of human GBM.  A number of different 
genetically engineered viruses have been constructed with deletions or mutations in 1 or more 
HSV genes in an effort to decrease toxicity of HSV to the CNS and provide a condition for viral 
replication only in replicating cells that can provide cellular homologues (206, 208).  Other HSV 
mutants have been constructed that are defective for immediate-early (IE) gene expression, 
resulting in replication-incompetent viruses.  Various genes have been inserted in these modified 
viruses for expression in infected cells (178, 244).  In our study, we found the HSV-1 virus alone 
can enhance the radiosensitivity of GBM. 
Advani et al., have shown the conditionally-replicative HSV-1 mutant, R3616, has 
greater oncolytic effects and increased replication when exposed to IR (4).  In their study, human 
U87-MG xenografts in mice underwent significantly greater reduction in tumor volume or total 
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regression when tumors were inoculated with the R3616 mutant and irradiated.   Increased 
spread of the virus was seen with in-situ hybridization with DNA probes to the virus.  Other 
studies have confirmed the enhanced tumoricidal effect of HSV when combined with IR (30, 
205).   
We believe targeting the repair of DNA DSBs in malignant glioma cells may be an 
important method to enhance the tumoricidal effect of IR.  Inhibition of DNA repair may also 
play a role in the chemotherapeutic treatment of GBM.  Use of an HSV-1 vector, which solely 
produces ICP0, may form the basis of future gene therapy strategies against human GBM.  
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4. INTRACEREBRAL CONVECTION-ENHANCED DELIVERY OF A HERPES 
SIMPLEX VIRUS VECTOR IN A MOUSE MODEL 
 
4.1. Abstract 
The less than optimal tissue distribution of HSV-1 vectors in the brain remains a limiting factor 
when considering the efficacy of various HSV-1 constructs for treatment of malignant gliomas.  
Convection-enhanced delivery (CED) of the replication-defective mutant, d106, resulted in 
homogeneous cell infection and extensive viral distribution in the mouse brain 48 hours after 
infusion.  Persistent transgene expression occurred up to 6 days after CED.  In addition, minimal 
viral reflux occurred along the catheter needle tract.  Heparin or dextran sulfate co-infusion 
diminished HSV-1 cell infection and viral spread.  Toxicity studies of intracerebral CED of d106 
revealed a local inflammatory response occurring within 6 days of infusion that resolved 21 days 
after infusion.  Local in vivo apoptosis was present on day 7 after d106 CED that was absent 
with Hanks’ balanced salt solution CED.  No animals showed any external signs of toxicity.  The 
ICP0-producing mutant, d106, may form the basis of future gene therapy studies for malignant 
gliomas by CED. 
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4.2. Introduction 
Herpes simplex virus-1 (HSV-1) recombinant vectors have been tested in multiple human 
clinical trials for the treatment of malignant gliomas (134, 252, 271).  The less than optimal 
tissue distribution of HSV-1 vectors in the brain remains a limiting factor when considering the 
efficacy of various HSV constructs for the treatment of malignant gliomas.  Delivery of HSV-1 
vectors in all clinical trials has been by multiple manual stereotactic intratumoral or peritumoral 
injections after surgical resection (134, 206).  Viral particles accumulate adjacent to the needle 
tract, and limited dispersal of particles occurs by diffusion.  The binding of viral particles to the 
heparan sulfate proteoglycans found abundantly in the extracellular matrix and glycocalyx in the 
brain may contribute to limited dispersal (350). 
Convection-enhanced delivery (CED) is an approach developed to overcome the 
obstacles associated with current CNS agent delivery (26, 230) and is increasingly used to 
distribute therapeutic agents for treatment of malignant gliomas.  Currently, multiple clinical 
trials involve CED for the treatment of recurrent GBM (182, 326, 336, 338).  In CED, a small 
hydrostatic pressure differential, imposed by a syringe pump to distribute infusate directly to 
small or large regions of the CNS, is used in a safe, reliable, targeted, and homogeneous manner 
(60).  CED relies on bulk flow that is driven by a small gradient to distribute molecules within 
the interstitial spaces of the CNS.  Convection is not limited by the infusate’s molecular weight, 
concentration, or diffusivity (26, 230, 310).   
Limited use of CED for viral vector delivery to the brain has been reported, mainly with 
the adeno-associated virus type 2 (AAV-2) (13, 61, 240).  In one study, the authors suggested 
heparin co-infusion significantly increased the volume of distribution of AAV-2 by blocking the 
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binding of virus to heparan sulfate proteoglycans in the extracellular matrix (240).  In the present 
study, we chose to deliver a replication-defective HSV mutant, d106, by intracerebral CED in a 
mouse model to determine cell infection, viral spatial distribution, and viral reflux along the 
needle tract.  Heparin or dextran sulfate co-infusion was also performed to determine whether 
viral spatial distribution could be augmented.  In addition, intracerebral viral toxicity was 
assessed after CED of the d106 virus.  
 
4.3. Material and Methods 
 
4.3.1. Animals and HSV-1 Vector 
Six- to 7-week old female BALB/c mice (Charles River Laboratories, Wilmington, MA) were 
used, and all procedures were performed in accordance with the guidelines of the Institutional 
Animal Care and Use Committee of the University of Pittsburgh.  The HSV-1 IE mutant virus, 
d106, is derived from the wild-type strain KOS and has been previously described (284).  The 
HSV-1 mutant, d106, is defective in the expression of all of the immediate-early (IE) viral genes 
except that which encodes ICP0 (284).  In place of the deletion of infected cell polypeptide (ICP) 
27, a green fluorescent protein (GFP) gene under the control of the human cytomegalovirus 
(HCMV) IE promoter is present. GFP transgene synthesis is abundant in d106-infected cells, in 
which ICP0 is expressed (284). 
 
4.3.2. CED Apparatus 
The infusion apparatus consisted of a hydraulic drive serially connected to a syringe pump (Sage 
Apparatus, ATI Orion, Boston, MA, Model 361) (Fig. 7).  This depressed the plunger of three 50 
µl oil-filled Hamilton syringes connected by cannulae made from polyetheretherketone (PEEK) 
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tubing (inner diameter 0.51 mm; Cole-Parmer Instrument Company, Vernon Hills, IL).  The 
distal end of each cannula was fitted with a 30-gauge hypodermic needle (Fisher Scientific, 
Hanover Park, IL) and glued in place.  The length of each cannula was measured to hold a 
volume of 120 µl.  HSV suspension or Hanks’ balanced salt solution (HBSS; Gibco Invitrogen 
Life Technologies, Inc., Grand Island, NY) was used to fill each cannula prior to attachment to  
each Hamilton syringe needle tip.  Each cannula end was secured to the electrode manipulator of 
a small animal stereotaxic instrument (Model 900, David Kopf Instruments, Tujunga, CA). 
 
 
Figure 10.  Convection-enhanced delivery mouse model.  A, Infusion apparatus holding three 50 µl Hamilton 
syringes filled with oil connected distally to cannulae made from PEEK tubing.  B, Anesthetized mouse placed in a 
small animal stereotaxic instrument and the CED cannula secured to the electrode manipulator of the stereotaxic 
instrument. 
 
4.3.3. HSV-1 CED and Heparin or Dextran Sulfate Co-infusion 
Mice were anesthetized with a ketamine/acepromazine mixture administered by the 
intraperitoneal route.  Anesthetized mice were placed in a stereotaxic instrument and an incision 
was made in the midline from the glabella to the occiput.  The underlying skull was exposed and 
a 2 mm burr hole was placed 0.5 mm anterior and 3 mm to the right of bregma.  Mice were 
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randomized into 4 groups of three animals each: (1) CED of d106, (2) CED of HBSS, (3) CED 
of d106 and heparin, (4) CED of d106 and dextran sulfate (10 or 100 µg). 
The CED cannula needle was inserted stereotactically through the burr hole to a depth of 
3 mm below the dural surface.  All animals underwent CED of 10 µl of d106 (3 x 107 pfu) 
suspension, HBSS, d106 (3 x 107 pfu) and heparin (1 unit), or d106 (3 x 107 pfu) with dextran 
sulfate (10 or 100 µg), at a rate of 1 µl/min.  After infusion completion, the cannula was left in 
place for 5 minutes to minimize any infusate leakback.  The cannula was then withdrawn at a 
rate of 1 mm/min and the craniotomy was sealed with bone wax and the scalp was re-
approximated by suture.  All animals were sacrificed 48 hours after CED.  Mouse brains were 
harvested and fixed with 10% neutral buffered formalin for histologic analysis. 
 
4.3.4. Persistent HSV-1 Transgene Expression and In vivo Toxicity 
Two separate groups of mice, 12 animals each, were randomized to undergo stereotactic 
intracerebral CED of 10 µl of d106 or HBSS at a rate of 1 µl/min.  Mice were sacrificed at 4, 6, 
7, and 21 days after CED.  Mouse brains were harvested and fixed with 10% neutral buffered 
formalin for histologic analysis. 
 
4.3.5. Histologic Analysis 
Upon brain fixation with formalin, coronal sections of each brain were made at the level of the 
needle tract to mark the center of virus or HBSS delivery.  Serial sections of the cerebral 
hemisphere were examined from each animal.  Tissue blocks were embedded in paraffin and 
sectioned (8 µm).  All sections were stained with hematoxylin and eosin. 
GFP immunohistochemistry was performed after deparaffination of tissue sections.  
Drying of tissue sections was performed initially.  Slides were then rinsed in deionized water and 
 71 
placed in a slide holder and a Tissue-Tek staining dish filled with Antigen retrieval solution 
(Abcam Inc., Cambridge, MA).  Slides were heated in a microwave oven until the antigen 
retrieval solution came to a boil and then were allowed to cool.  Slides were rinsed in phosphate 
buffered solution (PBS) prior to treatment with proteinase K.  Repeat rinsing with PBS was 
performed before the addition of 0.3% hydrogen peroxide to the slides to block endogenous 
peroxidase activity.  After rinsing with PBS, a permeabilizing/blocking solution consisting of 
PBS, 2% horse serum, and 0.2% Triton-X was added.  The blocking solution was removed and a 
primary rabbit polyclonal GFP antibody (sc-8334; Santa Cruz Biotechnology, Santa Cruz, CA), 
diluted 1:100 in PBS, was added in addition to 2% horse serum and 0.05% Tween 20 and 
incubated overnight at 4° C.  Slides were rinsed in PBS prior to addition of a biotinylated anti-
rabbit secondary antibody (dilution 1:100) provided in a rabbit ABC staining system (sc-2018; 
Santa Cruz Biotechnology, Santa Cruz, CA).  Incubation was performed for 30 minutes prior to 
rinsing of slides with PBS.  Incubation with a biotinylated horseradish peroxidase reagent was 
performed for 30 minutes and rinsing of slides was repeated with PBS.  Tissue sections were 
incubated in 1-3 drops of peroxidase substrate for 2-15 minutes until stain intensity was optimal.  
Counterstaining of tissue sections was performed in Mayer’s hematoxylin for 5 minutes prior to 
washing in running tap water.  Permanent mounting medium was added to each slide prior to 
glass coverslip placement. 
A terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling 
(TUNEL) assay was performed day 7 after CED of either d106 or HBSS on sections in 
accordance with the manufacturer’s instructions (Chemicon, Temecula, CA) and analyzed in a 
blinded fashion at 40X magnification by use of a light microscope. 
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Tissue sections were examined by light microscopy using a Nikon Diaphot 300 
photomicroscope (Melville, NY).  Images were captured by a SPOT RT camera (Diagnostic 
Instruments, Sterling Heights, MI) and imported into the SPOT version 3.5.9 for MacOS image 
analysis software package (Diagnostic Instruments, Sterling Heights, MI) running on a 
Macintosh G3 computer (Apple, Cupertino, CA). 
 
4.4. Results 
 
4.4.1. HSV-1 Cell Infection, Spatial Distribution, Reflux, and Transduction After CED 
The CED parameters chosen included a viral suspension volume of 10 µl infused at a rate of 1 
µl/min through a 30-gauge needle tip.  GFP transgene expression was used as a marker for cell 
infection in the brain.  Abundant cellular GFP expression has been shown in vitro 24 hours post-
infection by the d106 virus (284).  Intracerebral GFP expression was determined 2, 4, 6, 7, and 
21 days after stereotactic CED of d106 alone (Fig. 8).  Strong, homogeneous GFP staining was 
found adjacent to the needle tip, suggestive of uniform cell infection in the brain 2 days after 
CED.  Extensive viral spatial distribution within the gray matter of the brain was found away 
from the needle tip.  White matter tract distribution of HSV-1 was found distal to the needle tip 
and minimal infusate reflux occurred.  Persistent GFP expression, or cell infection, was found up 
to 6 days after CED of d106 (Fig. 9). 
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Figure 11.  Photomicrographs of mouse brain sections 48 hours after CED of d106.  Magnification, 40X.  A, 
Hematoxylin/eosin-stained section showing the catheter needle track on the left.  B, GFP-stained section showing 
viral cell infection and spatial distribution within the gray matter and white matter tracts. 
 
 
Figure 12.  Photomicrographs of mouse brain sections stained with GFP 4, 6, and 21 days after d106 CED.  
Persistent cell infection is present for 6 days.  Magnification, 40X.  A, Section day 4 after d106 CED.  B, Section 
day 6 after d106 CED.  C, Section day 21 after d106 CED revealing no GFP cell positivity. 
 
4.4.2. HSV-1 CED and Heparin or Dextran Sulfate Co-infusion 
The initial binding of HSV-1 to the cell surface occurs by heparan sulfate proteoglycans present 
on the surface of most types of vertebrate cells (350).  A potential problem in the delivery of 
HSV-1 by CED may be the binding of viral particles to the heparan sulfate proteoglycans found 
abundantly in the extracellular matrix and glycocalyx in the brain.  A prior report on CED of 
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AAV-2 to the rat brain, revealed abundant attachment of AAV-2 particles to cells adjacent to the 
injection tract limiting the distribution of AAV-2 when infused into the CNS parenchyma (240).  
Heparin co-infusion (2.5 units) significantly increased the volume of distribution of AAV-2 as 
demonstrated by immunoreactivity to a transgene product 6 days after infusion into the rat 
striatum.  No intracerebral hemorrhage was reported with heparin-coinfusion. 
 In our study, we chose to administer a lower dose of heparin (1 unit) with d106 into the 
mouse brain by CED to determine intracerebral infection and viral spatial distribution. 
Intracerebral GFP expression was determined 2 days after stereotactic CED.  Minimal cell 
infection occurred after CED of d106 and heparin together (Fig. 10).  Our results our consistent 
with prior in vitro studies, showing heparin inhibition of HSV-1 cell infection by masking the 
heparin sulfate binding domains on the virus envelope (350).  No intracerebral hemorrhage 
occurred in the animals that underwent heparin-coinfusion in our study. 
 
 
Figure 13.  Photomicrographs of mice brain sections after heparin or dextran sulfate (10 µg) co-infusion with d106.  
Immunohistochemistry staining for GFP was performed.  Magnification, 40X.  A, CED of d106 and heparin.  B, 
CED of d106 and dextran sulfate. 
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 Co-infusion of dextran sulfate with d106 was also performed to determine if cell 
infection and viral spatial distribution could be enhanced.  Dextran sulfate may serve as a 
substitute for heparin, which is not associated with anticoagulative effects.  In a prior report, 
dextran sulfate has been shown to interact with both HSV-1 virions and cells (80).  In that paper, 
a mutant cell line unable to produce glycosaminoglycans was treated with DS either prior to or 
during infection with HSV-1.  The use of dextran sulfate (10 or 100 µg) added either prior to or 
during inoculation stimulated HSV-1 infection by up to 35 fold.  Their results were consistent 
with a model in which DS effectively substitutes for heparan sulfate as a matrix to initiate viral 
adsorption at the cell surface. 
 We chose to co-infuse either 10 or 100 µg of dextran sulfate with d106 into the mouse 
brain.  Intracerebral GFP expression was determined 2 days after stereotactic CED.  All three of 
the animals that underwent CED of d106 and the higher dose of dextran sulfate (100 µg) died 
within 6 hours after infusion.  Co-infusion of the lower dose of dextran sulfate (10 µg) resulted 
in limited HSV-1 cell infection and viral distribution (Fig. 10).  Distribution of virus was found 
only along the needle tract.  Neither heparin or dextran-sulfate co-infusion resulted in any 
increase in cell infection or viral distribution in comparison to d106 CED alone.  Instead, heparin 
or dextran-sulfate co-infusion diminished cell infection and viral spread. 
 
4.4.3. Intracerebral Toxicity of d106 After CED 
We have previously shown in vitro that d106 infection of cells results in decreased cell survival 
in part by apoptosis induction (126, 284).  In addition, prior reports have confirmed the 
immunogenicity of HSV-1 replication-defective viruses both in vitro and in vivo (32, 33).  We 
chose to evaluate the toxicity of d106 in the mouse brain at 4, 6, 7, and 21 days after CED.  
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Inflammation, or encephalitis, was determined after hematoxylin/eosin preparation of brain 
sections.  In vivo apoptosis was determined on brain sections with TUNEL staining day 7 after 
CED.  No animals showed any signs of external toxicity such as weight loss or paresis.  
 
 
Figure 14.  Intracerebral toxicity of d106 after CED.  Photomicrographs of mice brain sections 4, 6, 7, and 21 days 
after d106 CED.  Magnification, 40X.  A-C, Hematoxylin/eosin-stained sections on days 4, 6, and 21.  D, In vivo 
apoptosis by TUNEL staining on day 7.  E, TUNEL staining after CED of HBSS on day 7. 
 
On day 4 after CED of d106, cell necrosis was present within the area of brain infused with d106 
with minimal surrounding inflammation (Figs. 11 and 9).  GFP cell expression was found at the 
periphery of the area of cellular necrosis.  A substantial inflammatory cell response adjacent to 
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the area of viral delivery was present on day 6 after d106 CED.  No intracerebral inflammation 
was present 21 days after d106 CED.  No intracerebral inflammation was present on days 4, 6, 7, 
and 21 days after HBSS CED. 
 In vivo apoptosis was present on day 7 after CED of d106 (Fig. 11).  The greatest number 
of apoptotic cells was found immediately adjacent to the catheter needle tip.  Cells undergoing 
apoptosis were found distal to the needle tip in a circumscribed, homogeneous distribution.  No 
in vivo apoptosis was present after CED of HBSS (Fig. 11). 
 
4.5. Discussion 
The method of HSV-1 delivery to tumors within the brain is critical to determining the efficacy 
of various recombinant constructs in the treatment of malignant gliomas.  In studies to date, 
manual stereotactic injection is the delivery method used (134, 206, 252, 271).  Such a technique 
is unlikely to result in widespread and uniform distribution of HSV-1 within tumor tissue as well 
as surrounding, tumor-invaded brain.  In addition, reflux of viral dose along the injection tract is 
an important problem that could impact on the dose of virus that reaches the tumor (204).  Intra-
arterial delivery has been examined as a potential mechanism of delivery for HSV-1, but 
obtaining adequate delivery of vector was also difficult via this route (153). 
We believe convection-enhanced delivery of HSV-1 is an optimal delivery approach to 
the brain.  Cell infection and distribution of HSV-1 appears relatively homogeneous in the brain 
after CED with a moderate dose of virus (3 x 107 pfu/10 µl).  Spread of viral particles occurs 
within the gray matter and along white matter tracts in the brain.  In addition, minimal viral 
reflux occurs along the catheter needle tract maximizing the viral dose available for cell 
infection.  Delivery of HSV-1 with heparin or dextran sulfate does not enhance cell infection and 
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viral distribution in the brain.  Instead, diminished cell infection and viral spatial distribution 
occurs after heparin or dextran sulfate co-infusion. 
 The potential use of replication-defective HSV-1 vectors in human trials for the therapy 
of malignant gliomas exists.  Prior to the use of any of these vectors in the clinic, adequate 
toxicity studies need to be performed.  The ICP0-producing mutant, d106, does elicit an initial 
local inflammatory response in the mouse brain that subsides 21 days after viral delivery.  An 
apoptotic mode of cell death is triggered within the area of viral infusion after 7 days.  No 
animals that underwent CED of d106 showed any external signs of toxicity such as weight loss 
or paresis. 
 Recently, we have shown the HSV-1 mutant, d106, inhibits DNA repair and enhances the 
radiosensitivity of human GBM cells in vitro (126).  We believe the replication-incompetent 
d106 virus may form the basis of future gene therapy studies for malignant gliomas by 
convection-enhanced delivery.   
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5. A HERPES SIMPLEX VIRUS VECTOR ENHANCES THE RADIOSENSITIVITY 
OF MOUSE INTRACRANIAL HUMAN GLIOBLASTOMA XENOGRAFTS AFTER 
CONVECTION-ENHANCED DELIVERY 
 
5.1. Abstract 
Improving the efficacy of herpes simplex virus 1 (HSV-1) therapy for malignant gliomas may 
require combination therapy with other treatment modalities and a change in the delivery of virus 
to tumor cells in the brain.  The goals of this study were the following:  (1) To compare 
convection-enhanced delivery (CED) of HSV-1 to stereotactic manual injection in viral spatial 
distribution, cell infection, and viral suspension reflux in the mouse brain;  (2) To determine U87 
MG xenograft infection and viral transduction in a mouse intracranial human glioma model after 
CED of the ICP0-producing HSV mutant, d106; (3) To determine whether radiosensitivity 
enhancement of intracranial malignant glioma xenografts occurs after CED of d106 in 
combination with whole-brain irradiation.  Stereotactic manual intracerebral injection and CED 
of HSV-1 was performed on BALB/c mice.  The volume for each method of delivery was 10 µl 
of d106 suspension (3 x 109 plaque forming units (pfu)/ml).  The rate of infusion for CED was 1 
µl/minute.  Viral spatial distribution and cell infection in the brain were determined by brain 
immunohistochemistry for enhanced green fluorescent protein (EGFP).  Intracranial U87-MG 
human GBM xenografts were established in athymic nude mice.  Mice were randomized to 
undergo intracranial CED (10 µl) of the replication-defective d106 virus (3 x 109 pfu/ml) or 
Hanks’ balanced salt solution (HBSS), at a rate of 1 µl/min prior to whole-brain irradiation (0 or 
10 Gy).  Superior brain viral spatial distribution and cell infection was found after CED of d106 
in comparison to stereotactic manual injection.  Minimal viral suspension reflux occurred during 
CED while reflux happened frequently with stereotactic injection.  Optimal xenograft infection 
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and persistent cell infection was found after CED of d106.  Combination therapy of d106 CED 
and irradiation resulted in xenograft regression and greater overall survival (P < 0.01) in animals.  
CED is superior to stereotactic injection of HSV-1 in viral delivery to the mouse brain.  
Combination therapy of d106 CED and whole-brain irradiation resulted in optimal xenograft 
HSV-1 delivery and enhancement of the effects of radiation in an intracranial malignant glioma 
model. 
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5.2. Introduction 
Herpes simplex virus 1 (HSV-1) is a double-stranded DNA virus that has been studied for use in 
the treatment of human malignant gliomas, the most devastating and therapy-resistant central 
nervous system (CNS) tumors in adults.  A number of different genetically engineered oncolytic 
viruses have been constructed with deletions or mutations in one or more HSV genes (γ134.5, 
UL39 (ribonucleotide reductase), tk, and UTPase) in an effort to decrease the toxicity of HSV to 
the CNS and provide a condition for viral replication only in replicating cells that can provide 
cellular homologues (49, 51, 152, 175, 208, 222, 267).  Phase I clinical studies in humans with 
malignant gliomas have demonstrated modest antitumor effect with HSV-1 oncolytic viruses 
(134, 206, 271).  Other HSV mutants have been constructed that are defective for immediate-
early (IE) gene expression, resulting in replication-incompetent viruses that are nontoxic to cells 
(284).  Various genes have been inserted in these modified viruses for expression in infected 
cells (178, 202, 229, 244).   
Improving the efficacy of HSV-1 therapy for malignant gliomas may require combination 
therapy with other treatment modalities and a change in the delivery of virus to tumor cells in the 
brain.  Prior studies have shown that HSV replication and tumor kill in human GBM xenografts 
is increased when the oncolytic virus, R3616, is administered in conjunction with ionizing 
radiation (IR) (4).  Other studies have confirmed the tumoricidal effect of HSV when combined 
with IR (30, 205).  
In all human Phase I and animal studies, HSV delivery is by direct manual stereotactic 
injection into the brain (134, 206, 271).  In the human studies performed, viral injection is 
performed multiple times within the contrast-enhancing portion of the tumor or around the 
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resulting cavity after surgical resection (134, 205, 271).  Stereotactic intracerebral injection of 
HSV-1 vectors has produced limited success in the delivery of the virus to brain tumor cells 
(206, 229, 270).  Besides the difficult task of standardizing distances between injection tracts and 
applied volumes, reflux of vector suspension from needle tracks is invariably encountered with 
manual injection (204, 270).  Viral particles accumulate adjacent to the needle tract and limited 
dispersal of particles occurs by diffusion (24).  The binding of viral particles to the heparan 
sulfate proteoglycans found abundantly in the extracellular matrix and glycocalyx in the brain 
may contribute to limited dispersal (350). 
Convection-enhanced delivery (CED) is an approach developed to overcome the 
obstacles associated with current CNS agent delivery (26, 230) and is increasingly used to 
distribute therapeutic agents for treatment of malignant gliomas.  Currently, multiple clinical 
trials involve CED for the treatment of recurrent GBM (182, 326, 336, 338).  In CED, a small 
hydrostatic pressure differential, imposed by a syringe pump to distribute infusate directly to 
small or large regions of the CNS, is used in a safe, reliable, targeted, and homogeneous manner 
(60).  CED relies on bulk flow that is driven by a small gradient to distribute molecules within 
the interstitial spaces of the CNS.  Convection is not limited by the infusate’s molecular weight, 
concentration, or diffusivity (26, 230, 310).  Limited use of CED for viral vector delivery to the 
brain has been reported, mainly with the adeno-associated virus 2 (AAV-2) (13, 61). 
We have recently shown the replication-defective HSV-1 vector, d106, inhibits DNA 
repair and enhances the radiosensitivity of human GBM cells (126).  The mutant virus, d106, is 
defective in the expression of all of the IE viral genes except that which encodes ICP0 (284).  
Expression of the ICP0 protein by d106 results in degradation of the catalytic subunit of DNA-
dependent protein kinase (DNA-PKCS) in human GBM cells.  DNA-PKCS is a key component of 
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the nonhomologous end-joining (NHEJ) DNA repair pathway that is thought to repair the 
majority of DNA double-strand breaks.  Inhibition of the repair of DNA double-strand breaks 
after IR (5, 10, or 20 Gy) results in a significant decrease in survival of GBM cells in part by 
induction of apoptosis.  ICP0 has also been shown by our group to induce cell cycle arrest in G1 
and G2-M independently of p53 (143).  In the present study, we chose to deliver d106 by 
intracerebral stereotactic injection or CED in normal mice to compare cell infection, viral spatial 
distribution, and viral suspension reflux by each modality.  In addition, intracerebral CED of 
d106 was performed in a mouse glioma model in combination with ionizing radiation (IR) to 
determine U87 MG xenograft infection and transduction, viral antitumor effect, and mouse 
survival.   
 
5.3. Material and Methods 
 
5.3.1. Animals, Cells, and HSV-1 Vector 
Six- to 7-week old female athymic nude (nu/nu) and BALB/c mice (Charles River Laboratories, 
Wilmington, MA) were used, and all procedures were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee of the University of Pittsburgh.  
The human glioblastoma cell line, U87 MG, was obtained from the American Type Culture 
Collection (ATCC) and maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with sodium pyruvate, non-essential amino acids, antibiotics, and 10% fetal 
bovine serum (FBS) (Invitrogen Life Technologies, Inc., Gaithersburg, MD).  The HSV-1 IE 
mutant virus, d106, is derived from the wild-type strain KOS and has been previously described 
(284).  In place of the deletion of infected cell polypeptide (ICP) 27, a green fluorescent protein 
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(GFP) transgene under the control of the human cytomegalovirus (HCMV) IE promoter was 
inserted.  GFP transgene synthesis is abundant in d106-infected cells, in which ICP0 is present 
 
5.3.2. CED Apparatus 
The infusion apparatus consisted of a hydraulic drive serially connected to a syringe pump (Sage 
Apparatus, ATI Orion, Boston, MA, Model 361).  This depressed the plunger of three 50 µl oil-
filled Hamilton syringes (Hamilton Co., Reno, NV) connected by cannulae made from 
polyetheretherketone (PEEK) tubing (inner diameter 0.51 mm; Cole-Parmer Instrument 
Company, Vernon Hills, IL).  The distal end of each cannula was fitted with a 30-gauge 
hypodermic needle (Fisher Scientific, Hanover Park, IL) and glued in place.  The length of each 
cannula was measured to hold a volume of 120 µl.  HSV solution or Hanks’ balanced salt 
solution (HBSS; Gibco Invitrogen Life Technologies, Inc., Grand Island, NY) was used to fill 
each cannula prior to attachment to each Hamilton syringe needle tip.  Each cannula end was 
secured to the electrode manipulator of a small animal stereotaxic instrument (Model 900, David 
Kopf Instruments, Tujunga, CA). 
 
5.3.3. Tumor Inoculation, HSV-1 Convection Procedure, and Irradiation 
Mice were anesthetized with a ketamine/acepromazine mixture administered by the 
intraperitoneal route.  Anesthetized mice were placed in the stereotaxic instrument and an 
incision was made in the midline from the glabella to the occiput.  The underlying skull was 
exposed and a 2 mm burr hole was placed 0.5 mm anterior and 3 mm to the right of bregma.  
U87 MG cells (5 x 105) in a 5 µl volume were stereotactically inoculated into the right striatum, 
3 mm below the dural surface on day 0, with a 10 µl Hamilton syringe fitted into a syringe 
holder microinjection unit (Model 5000, David Kopf Instruments, Tujunga, CA) and secured to 
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the small animal stereotaxic instrument.  After removal of the injection needle, the craniotomy 
was sealed with bone wax and the scalp was re-approximated by suture.  On day 5 post-tumor 
implantation, mice were randomized into four groups (Table 1):  (1) CED of HBSS (untreated 
control), (2) CED of HBSS and irradiation, (3) CED of d106 alone, (4) CED d106 and 
irradiation.   
 
Table 1. 
 
Treatment groups          Protocol   Median survival  Survival  
(n=10)   Day 5  Day 7   (days)   at 80 d (%)  
  
1.  HBSS (control) CED HBSS 0 Gy   23   0 
 
2.  HBSS + IR CED HBSS 10 Gy   39   0 
 
3.  d106  CED d106 0 Gy   41   0 
 
4.  d106 + IR  CED d106 10 Gy   68   30 
 
Table 1.  Summary of treatment group results including number of animals, protocol, median survival, and percent 
survival at 80 days. 
 
All animals underwent CED of 10 µl of d106 (3 x 107 pfu) suspension or HBSS at a rate 
of 1 µl/min on day 5.  Anesthetized mice were placed back in the stereotactic head frame and the 
previous skin incision was opened.  The CED cannula needle was inserted stereotactically 
through the previous craniotomy using the same coordinates as used earlier for tumor cell 
implantation.  After infusion completion, the cannula needle was left in place for 5 minutes to 
minimize any infusate leakback.  The cannula needle was then withdrawn at a rate of 1 mm/min 
and the craniotomy was sealed with bone wax and the scalp was re-approximated by suture. 
A single dose of IR (10 Gy) was delivered to anesthetized mice on day 7 in a 137Cs 
animal irradiator (Gammacell40, Atomic Energy of Canada Limited, Ontario, Canada) at a dose 
rate of .87 Gy/min.  A lower dose of ionizing radiation was chosen to have modest antitumor 
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effect but to not be curative.  Perforated collimator plates were used for selective whole-brain 
irradiation of animals.  
 
5.3.4. Intracerebral HSV-1 CED or Stereotactic Injection Alone 
Intracerebral stereotactic CED or injection of d106 was performed in six BALB/c mice after 
anesthesia and placement in the small animal stereotaxic instrument.  CED was performed as 
described previously.  Injection was performed in the same fashion as tumor inoculation 
described previously.  Briefly, 10 µl of d106 (3 x 107 pfu) suspension was manually injected 
through a 10 µl Hamilton syringe secured to the syringe holder microinjection unit attached to 
the small animal stereotaxic instrument.  The syringe needle was stereotactically inserted into a 2 
mm burr hole placed 0.5 mm anterior and 3 mm to the right of bregma.   Injection was initiated 3 
mm below the dural surface.  The injection needle was left in place for 5 minutes prior to 
removal.  All animals were sacrificed 48 hours after intracerebral CED or injection and brains 
were harvested for histologic analysis. 
 
5.3.5. Animal Observation 
All mice were observed daily to monitor external appearance, feeding behavior, and locomotion.  
The contralateral limbs were observed for the development of paresis.  Animals were sacrificed 
at the first sign of an adverse event (paresis, inability to feed) and brains were removed for 
histological examination.  On days 5, 7, 9, 12, 15, and 17, three animals from each group of 
animals inoculated with tumor were randomly sacrificed for histologic analysis of intracranial 
tumor burden and U87 MG xenograft d106 infection.  All remaining animals surviving 80 days 
after tumor implantation were sacrificed. 
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5.3.6. Histologic Analysis 
Mouse brains were harvested and fixed with 10% neutral buffered formalin.  Coronal sections 
were made at the level of the needle tract to mark the center of the tumor.  Serial sections of the 
cerebral hemisphere were examined from each animal.  Tissue blocks were embedded in paraffin 
and sectioned (5 µm).  All sections were stained with hematoxylin and eosin.   
GFP immunohistochemistry was performed after deparaffination of tissue sections.  
Drying of tissue sections was performed initially.  Slides were then rinsed in deionized water and 
placed in a slide holder and a Tissue-Tek staining dish filled with Antigen retrieval solution 
(Abcam Inc., Cambridge, MA).  Slides were heated in a microwave oven until the antigen 
retrieval solution came to a boil and then were allowed to cool.  Slides were rinsed in phosphate 
buffered solution (PBS) prior to treatment with proteinase K.  Repeat rinsing with PBS was 
performed before the addition of 0.3% hydrogen peroxide to the slides to block endogenous 
peroxidase activity.  After rinsing with PBS, a permeabilizing/blocking solution consisting of 
PBS, 2% horse serum, and 0.2% Triton-X was added.  The blocking solution was removed and a 
primary rabbit polyclonal GFP antibody (sc-8334; Santa Cruz Biotechnology, Santa Cruz, CA), 
diluted 1:100 in PBS, was added in addition to 2% horse serum and 0.05% Tween 20 and 
incubated overnight at 4° C.  Slides were rinsed in PBS prior to addition of a biotinylated anti-
rabbit secondary antibody (dilution 1:100) provided in a rabbit ABC staining system (sc-2018; 
Santa Cruz Biotechnology, Santa Cruz, CA).  Incubation was performed for 30 minutes prior to 
rinsing of slides with PBS.  Incubation with a biotinylated horseradish peroxidase reagent was 
performed for 30 minutes and rinsing of slides was repeated with PBS.  Tissue sections were 
incubated in 1-3 drops of peroxidase substrate for 2-15 minutes until stain intensity was optimal.  
Counterstaining of tissue sections was performed in Mayer’s hematoxylin for 5 minutes prior to 
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washing in running tap water.  Permanent mounting medium was added to each slide prior to 
glass coverslip placement.   
Tissue sections were examined by light microscopy using a Nikon Diaphot 300 
photomicroscope (Melville, NY).  Images were captured by a SPOT RT camera (Diagnostic 
Instruments, Sterling Heights, MI) and imported into the SPOT version 3.5.9 for MacOS image 
analysis software package (Diagnostic Instruments, Sterling Heights, MI) running on a 
Macintosh G3 computer (Apple, Cupertino, CA). 
 
5.3.7. Statistical Analysis 
Survival data were entered into Kaplan-Meier plots and statistical analysis was performed using 
a log-rank test.  A P value of 0.05 was used as the boundary of statistical significance. 
 
5.4. Results 
5.4.1. HSV-1 Stereotactic Injection vs. CED 
HSV-1 intracerebral cell infection, spatial distribution, and reflux along the needle tract were 
determined in the normal mouse brain after stereotactic CED or injection.  GFP transgene 
expression was used as a marker for cell infection.  Abundant cellular GFP expression has been 
shown in vitro 24 hours post-infection by the d106 virus (284).  GFP expression was determined 
48 hours after stereotactic CED or injection of d106.  A 10 µl suspension of d106, containing 3 x 
107 pfu, was used with each method of delivery.  Histologic analysis of tissue sections along 
either the cannula or syringe needle tract revealed both greater spatial distribution and intensity 
of GFP staining after CED of d106 in comparison to stereotactic injection (Fig. 12).  Strong, 
homogeneous GFP expression after CED suggests greater cell infection by d106.  White matter 
tract spread of HSV-1 was found after CED but not with stereotactic injection.  Vector 
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suspension reflux along the needle tract was present with manual stereotactic injection while 
minimal infusate leakback occurred after CED (Fig. 12).   
 
 
Figure 15.  Photomicrographs of BALB/c mice brain sections after immunohistochemistry staining for GFP.  A 
comparison of intracerebral manual stereotactic injection and convection-enhanced delivery (CED) with 10 µl of 
d106 viral suspension (3 x 107 pfu) revealing greater cell infection and viral spatial distribution with minimal viral 
reflux after CED.  A. Manual stereotactic injection (Magnification, 40X).  B. Stereotactic CED (Magnification, 
40X).  C. Viral reflux along the needle tract after manual stereotactic injection (Magnification, 100X). 
 
5.4.2. HSV-1 Xenograft Infection and Cell Transduction 
After inoculation of athymic nude mice with U87 MG tumor cells, CED of d106 or HBSS was 
performed 5 days later.  Intracerebral GFP expression was determined at 7, 9, 12, 15, and 17 
days after xenograft placement (Fig. 13; Table 2).  Intratumoral expression of GFP was found in 
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75% (9 of 12 animals) of the animals that underwent CED of d106 and were randomly sacrificed 
at 7 and 9 days post-tumor implantation (2 and 4 days after d106 CED) (Figs. 13A and 13C).  
Two of the 9 animals had minimal intra-tumoral GFP expression (Fig. 13B).  All animals that did 
not have intratumoral expression of GFP had peri-tumoral cell expression of GFP, indicating 
inadequate penetration of the xenograft by the d106 virus.  Persistent cellular GFP transgene 
expression was found up to 12 days after d106 CED in cells within and surrounding xenograft 
sites (Fig. 13D) after tumor regression. 
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Figure 16.  Photomicrographs of athymic nude mice brain sections containing U87 MG xenografts after stereotactic 
intracerebral CED of d106.  Magnification, 40X.  A. Hematoxylin/eosin-stained section day 7 after tumor 
implantation and 2 days after d106 CED revealing boundaries of xenograft (left); corresponding GFP-stained section 
revealing marked xenograft infection and viral spatial distribution into the surrounding brain (right).  B. 
Hematoxylin/eosin-stained section day 7 after tumor implantation (left) and corresponding GFP-stained section 
(right) revealing minimal xenograft infection and viral spatial distribution.  C. GFP-stained section day 7 showing 
strong xenograft infection and extensive viral spatial distribution within the tumor.  D. Hematoxylin/eosin-stained 
section day 17 after tumor implantation (left) and corresponding GFP-stained section (right) revealing complete 
tumor regression and continued GFP expression at the xenograft site suggestive of persistent viral infection. 
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5.4.3. Antitumor Effect of d106 and IR 
Survival studies were performed on animals that underwent CED of HBSS or d106 and whole-
brain irradiation (0 or 10 Gy).  A total of 4 groups, consisting of 10 animals each, were used for 
survival analysis at a 80-day post tumor induction survival mark (Table 1).  The median survival 
for control animals that underwent CED of HBSS and no irradiation was 23 days.  Those animals 
that underwent CED of d106 and were not irradiated had a median survival of 41 days.  Median 
survival was significantly increased (P< 0.01 by log-rank method) when animals underwent 
CED of d106 in comparison to control animals.  Animals that had HBSS CED and were 
irradiated (10 Gy) had a median survival of 39 days.  Animals that underwent CED of d106 and 
were irradiated had a median survival of 68 days.  Of these animals, 30% were still alive on day 
80 when sacrificed.  Median survival was significantly increased (P< 0.01 by log-rank method) 
when animals underwent CED of d106 and subsequent whole-brain irradiation (10 Gy) in 
comparison to animals that underwent CED of HBSS and irradiation (Fig. 14).   
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Figure 17.  Kaplan-Meier survival curves of athymic nude mice after intracranial implantation of U87-MG cells and 
treatment by stereotactic CED of d106 or HBSS and irradiation (0 and 10 Gy).  Control animals were mice that 
underwent CED of HBSS and did not receive ionizing radiation.  Statistical significance, P < 0.001 by log-rank 
method of CED of d106 and irradiation compared to CED HBSS and irradiation (n=10 per group).  Animals 
surviving 80 days post-tumor implantation were sacrificed. 
Partial regression of xenograft was found in all three animals randomly sacrificed day 12 post 
tumor implantation after undergoing d106 CED and irradiation (Fig. 15A; Table 2).  Complete 
tumor regression was found in three of six animals randomly sacrificed on days 15 and 17 post-
tumor induction, which underwent d106 CED and irradiation (Figs. 13D and 15B; Table 2).  
Partial regression of tumor was found in the other three animals. 
 
Table 2. 
Intra-tumoral GFP  Partial tumor    Complete tumor  
expression days 7/9  regression day 12   regression days 15/17  
after d106 CED (%)  after d106 CED + IR (%)  after d106 CED + IR (%) 
 
 9/12 (75)   3/3 (100)    3/6 (50) 
 
Table 2.  Summary of U87-MG xenograft infection rate and treatment response in animals that underwent d106 
CED and whole-brain irradiation that were randomly sacrificed.  GFP xenograft infection was determined in animals 
from treatment groups 3 and 4 on days 7 and 9 post tumor implantation.  Treatment response was determined in 
treatment group 4 on days 12, 15, and 17 post tumor implantation.   
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Figure 18.  Photomicrographs of brain sections revealing antitumor efficacy of stereotactic CED of d106 in 
combination with ionizing radiation (10 Gy) in athymic nude mice implanted with U87-MG xenografts.  
Magnification, 40X.  A, Hematoxylin/eosin- (left) and GFP-stained (right) sections day 12 after tumor implantation 
and 7 days after d106 CED showing regression of xenograft.  B, GFP-stained section revealing complete tumor 
regression on day 17 after tumor implantation.  C, Hematoxylin/eosin-stained section day 17 after tumor 
implantation in animal that underwent intracerebral CED of HBSS and irradiation showing a large tumor. 
5.5. Discussion 
Radiation therapy remains the sole agent that increases the survival of patients with GBM but 
provides modest benefit (191, 330, 331).  Combining the effects of ionizing radiation and HSV-1 
in the therapy of malignant gliomas has been reported in multiple studies (4, 30, 205) and is 
currently being developed into a human clinical protocol (204).  Both oncolytic and replication-
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defective HSV-1 constructs have been used with ionizing radiation.  HSV replication and tumor 
kill is increased with oncolytic viruses utilizing large fractions of IR (20 and 25 Gy) (4, 30).  In 
the case of replication-defective viruses, greater animal survival has been shown with the 
combination of radiosurgery (margin dose of 15 Gy; center dose of 21.4 Gy) and HSV-1 
constructs that express the HSV-1 genes, ICP0 and tk, in addition to multiple transgenes (244, 
245).  In all these studies, delivery of HSV-1 is by stereotactic intratumoral manual injection 
resulting in suboptimal delivery of virus to tumor cells.   
Our group has recently shown that the HSV-1 immediate-early protein, ICP0, naturally 
inhibits the repair of DNA double-strand breaks after IR treatment of GBM cells leading to 
decreased cell survival and induction of apoptosis in vitro (126).  ICP0 has many effects on cell 
metabolism and has been proposed to promote lytic HSV infections by destabilizing cellular 
proteins that inhibit the lytic viral life cycle (127).  ICP0 has been shown by our group to inhibit 
the circularization of HSV-1 genomes and promote lytic infection (156).   
We present evidence showing intracerebral CED of the ICP0-producing HSV-1 mutant, 
d106, in combination with a single fraction of whole-brain irradiation (10 Gy), enhances the 
survival of animals implanted with U87-MG xenografts.  The radiation dose used in our study is 
approximately half the dose used in other studies (4, 244).  We believe optimal intracerebral 
HSV-1 delivery, by CED, allows for greater xenograft infection, transduction, and ultimate 
tumor cell demise by radiosensitivity enhancement.  Tumor regression is felt to occur by ICP0 
targeting of tumor cell repair of DNA double-strand breaks after irradiation and apoptosis 
induction.  Our results show that intracerebral HSV-1 CED does lead to greater cell infection and 
viral spatial distribution than manual stereotactic injection in the normal mouse brain.  In 
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addition, minimal viral reflux occurs along the catheter needle tract by CED, maximizing the 
viral dose available for cell infection. 
Targeting the repair of DNA after irradiation in tumor cells and maximizing the delivery 
of HSV-1 to tumor cells and the surrounding brain where tumor-infiltration has occurred may 
form the basis of future clinical gene therapy strategies against malignant gliomas.  
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6. SUMMARY AND DISCUSSION 
 
6.1. Summary of Results 
The study presented here describes the effects of HSV-1 infection on cellular DNA repair after 
ionizing radiation exposure.  Experiments were designed to identify the HSV IE protein, ICP0, 
as an inhibitor of DNA repair that enhances the radiosensitivity of experimental GBM.  A mouse 
model was developed to optimize the delivery of HSV-1 to the brain and determine the 
intracerebral toxicity of the ICP0-producing mutant, d106.  Intracerebral CED of the d106 was 
performed to determine the in vivo effects of ICP0 on human GBM xenografts in a mouse model.  
 In Chapter 3 it was determined that expression of ICP0 in human GBM cells inhibits the 
repair of DNA DSBs after IR treatment, decreasing the survival and proliferation of these cells in 
part by apoptosis induction.  Infection of two radioresistant human GBM cell lines, U87-MG and 
T98, by the ICP0-producing virus, d106, followed by IR treatment, resulted in a significant dose-
dependent decrease (5, 10, or 20 Gy) in cell proliferation and survival by the MTT assay after 6 
days compared with cells receiving only IR.  The greatest decrease in cell survival and 
proliferation occurred at the highest IR dose of 20 Gy (p< 0.005). (284).  Infection of both cell 
lines with d106 resulted in cell toxicity as proliferation and cell viability decreased soon after 
infection (P< 0.05).  Infection of both cell lines by the IE-deficient virus, d109, did not result in a 
dose-dependent decrease in cell proliferation and survival after IR treatment.  Cell proliferation 
occurred in both cell lines after d109 infection in the absence of irradiation consistent with the 
documented lack of toxicity upon d109 infection (284).  U87-MG cells infected with the ICP0-
producing adenovirus, AdS.11E4(ICP0), showed a decrease in cell survival and proliferation 
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after irradiation in comparison to cells which were only irradiated (P< 0.005), confirming the 
effect of ICP0 on cell survival and proliferation in GBM cells.  One-thousand fold less ICP0 is 
expressed from this construct relative to the level of expression from d106 (144).  Clonogenic 
survival assays confirmed the cytotoxic effects of ICP0 and IR.  The survival fraction was lowest 
among cells that were infected by d106 and irradiated compared to cells that solely were 
irradiated or infected with d106.  Apoptosis was determined to be a mode of GBM cell death 
with ICP0 production and IR exposure.  Levels of cleaved caspase-3 (p17) were detected in U87-
MG cells that were infected by d106 and irradiated.  Lower levels of cleaved caspase-3 were 
found in cells that were d106 infected but did not undergo irradiation.  Both groups of cells that 
were mock infected and did or did not receive IR had minimal detectable levels of cleaved 
caspase-3. Carboxyfluorescein poly-caspase detection performed with flow cytometry revealed 
greater numbers of U87-MG cells undergoing apoptosis when infected with d106 and irradiated 
than when infected or irradiated alone.  The percentage of d106-infected cells undergoing 
apoptosis were very similar 24 h after irradiation at 5, 10, or 20 Gy.  Minimal apoptosis was 
detected in mock infected cells that did or did not undergo irradiation confirming the results of 
our Western analysis of cleaved caspase-3 levels.  Degradation of DNA-PKcs was shown in both 
GBM cell lines 6 to 24 hours postinfection by d106.  Indirect immunofluorescence performed on 
both cell lines, preinfected with d106, revealed abundant and persistent γ-H2AX foci at 2, 6, and 
24 h post irradiation.  Cells infected by d106 and not irradiated had persistent γ-H2AX foci at 6 
and 24 h post-irradiation.  These results suggest linear HSV-1 genomes present after infection 
may be treated as DNA DSB with formation of γ-H2AX foci.  The greater number of γ-H2AX 
foci and persistence of these foci after irradiation suggests ICP0 inhibits DNA repair in human 
glioblastoma cells. 
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 In Chapter 4, optimal delivery of HSV-1 to the brain was investigated by CED in a 
mouse model.  GFP transgene expression by the d106 virus, was used as a cell marker for cell 
infection in the brain.  Strong, homogeneous GFP staining was found adjacent to the catheter 
needle tip, suggestive of uniform cell infection in the brain 2 days after CED.  Extensive viral 
spatial distribution within the gray matter of the brain was found away from the needle tip.  
White matter tract distribution of HSV-1 was found distal to the needle tip and minimal infusate 
reflux occurred.  Persistent GFP expression, or cell infection, was found up to 6 days after CED 
of d106.  Neither heparin or dextran-sulfate co-infusion with d106 resulted in any increase in cell 
infection or viral distribution in comparison to d106 CED alone.  Instead, heparin or dextran-
sulfate co-infusion diminished cell infection and viral spread.  Toxicity studies of intracerebral 
CED of d106 revealed a local inflammatory response occurring within 6 days of infusion that 
resolved 21 days after infusion.  Local in vivo apoptosis was present on day 7 after d106 CED 
that was absent with Hanks’ balanced salt solution CED.  No animals showed any external signs 
of toxicity. 
 In Chapter 5, the use of d106 as a potential antiglioma viral vector was investigated in a 
mouse glioma model.  Initial comparison of intracerebral HSV-1 delivery by manual stereotactic 
injection and CED in the normal mouse brain revealed greater cell infection and viral distribution 
after CED.  Viral vector suspension reflux along the needle tract occurred after stereotactic 
manual injection while minimal reflux occurred with CED.  The majority of human GBM (U87-
MG) xenografts implanted in athymic nude mice were infected by the d106 virus 7 and 9 days 
post-tumor implantation.  Persistent cellular transgene expression, or HSV-1 transduction, was 
found up to 12 days after d106 CED in cells within and surrounding the xenograft sites.  Survival 
studies were performed on animals that underwent CED of HBSS or d106 and whole-brain 
 100 
irradiation (0 or 10 Gy). The median survival for control animals that underwent CED of HBSS 
and no irradiation was 23 days.  Those animals that underwent CED of d106 and were not 
irradiated had a median survival of 41 days.  Animals that had HBSS CED and were irradiated 
(10 Gy) had a median survival of 39 days.  Animals that underwent CED of d106 and whole-
brain irradiation had a median survival of 68 days.  Of these animals, 30% were alive at the 80 
day survival mark post tumor implantation.  Median survival was significantly increased (P< 
0.01 by log-rank method) when animals underwent CED of d106 and subsequent whole-brain 
irradiation (10 Gy) in comparison to animals that underwent CED of HBSS and irradiation.  
Partial regression of xenograft was found in all three animals randomly sacrificed day 12 post 
tumor implantation after undergoing d106 CED and irradiation.  Complete tumor regression was 
found in three of six animals randomly sacrificed on days 15 and 17 post tumor induction, which 
underwent d106 CED and irradiation.  Partial regression of tumor was found in the other three 
animals. 
 
6.2. Role of ICP0 in Cellular DNA Repair 
ICP0 has many effects on cell metabolism and has been proposed to promote lytic HSV 
infections by destabilizing cellular proteins that inhibit the lytic viral life cycle (127).  Recently, 
the concept of HSV genome circularization as a requirement for viral DNA replication has been 
challenged.  Genome circularization does not occur in productive infection but instead may occur 
during establishment of latency as a function of ICP0 expression (156, 288).  ICP0 appears to 
prevent the formation of circular HSV-1 DNA molecules.  HSV-1 mutants defective for ICP0 
expression result in the predominance of circular HSV-1 genomes during infection.  The finding 
that ICP0 appears to prevent the formation of circular molecules may explain why replication of 
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HSV-1 is greatly reduced in HSV-1 mutants defective in ICP0 at low multiplicities of infection 
(283, 309).  Thus, linear HSV molecules rather than circles might serve as the initial templates 
for HSV-1 replication.   
The presence of linear HSV-1 genomes in the nucleus, early in infection, induces a 
cellular response to DNA damage with recruitment of recombination and repair proteins to HSV-
1 DNA (156, 193, 346).  Activation and exploitation of a cellular DNA damage response has 
been shown to aid viral replication.  The ends of the HSV-1 linear genomes may be treated as 
DNA DSBs with cellular repair processes activated to promote circularization of the viral 
genomes and a viral latent state.  ICP0 inhibition of genome circularization by cellular DNA 
repair disruption may occur by ND10 disruption and degradation of DNA-PKCS.  ND10 domains 
have been shown to contain host recombination/repair proteins (235) and participate in the cell’s 
response to DNA damage (41).  ND10 domains are redistributed in response to DNA damage 
(41), and it has been proposed that ND10 may store and release proteins in response to viral 
infection and DNA damage (235).  Degradation of DNA-PKCS and inhibition of NHEJ, the main 
DNA DSB repair pathway in mammalian cells, may further aid viral replication and production 
of viral progeny.  
The combination of IR-induced DNA DSBs and cell ICP0 production triggers cell death 
in human GBM cells in part by apoptosis induction.  The mechanism for cell death appears to be 
the overwhelming persistence of DNA DSBs that go unrepaired due to DNA repair inhibition by 
ICP0.  It is well known, that one unrepaired DSB can be sufficient to kill a cell if it inactivates an 
essential gene or triggers apoptosis (274).   
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6.3. Therapy of Human GBM with d106 
Phase I clinical studies in humans with GBM tumors have demonstrated modest antitumor effect 
with HSV-1 oncolytic viruses (134, 206, 271).  HSV-1 delivery has been by manual stereotactic 
injection into the brain.  Improving the efficacy of HSV-1 therapy for malignant gliomas requires 
multimodal therapy and a change in the delivery of virus to tumor cells in the brain.  Prior 
studies have shown an enhanced tumoricidal effect of oncolytic, HSV-1 mutants when combined 
with IR (30, 205).   
 In this study, the replication-defective mutant virus, d106, has shown antitumor effects 
when combined with IR both in vitro and in vivo.  The tumoricidal property of d106 is due to the 
effects of ICP0, as it does not express any other IE proteins.  One important effect of ICP0 may 
be the inhibition of DNA repair in cells.  Combining IR and d106 infection may overwhelm the 
cell’s ability to repair DNA damage, leading the cell to death.   
 The toxicity of intracerebral d106 infusion in the normal mouse brain has been confirmed 
in this study.  An inflammatory response occurs after d106 delivery to the brain and normal cells 
undergo apoptosis within the vicinity of d106 infusion.  The inflammatory response in the brain 
resolves as persistent infection is attenuated due to the non-replicative properties of d106. 
 The delivery of any HSV-1 mutant into the brain for therapy against GBM needs to be 
critically evaluated.  Stereotactic manual injection does not allow for widespread and uniform 
distribution of HSV-1 within the brain and tumor tissue.  Instead, reflux of viral dose occurs 
along the needle tract that impacts on the dose of virus that reaches tumor.  In this study, CED 
allows for greater cell infection and viral distribution in the normal mouse brain in comparison to 
stereotactic manual injection.  In addition, CED maximizes the local delivery of HSV-1 to 
human GBM xenografts implanted within the mouse brain. 
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The effective regression of intracranial glioblastoma xenografts after CED of d106 in 
combination with whole-brain irradiation may be explained by greater cell infection by 
convection and uniform irradiation of xenografts.  The possibility exists that a “bystander effect” 
from the ICP0 protein may contribute to xenograft regression since only a fraction of tumor cells 
appear virally infected after d106 CED.  In addition, an inflammatory response generated by 
d106 viral particles and virally infected cells may contribute to xenograft regression even in the 
absence of a T-cell mediated immune response in athymic nude mice.  
Targeting the repair of DNA after irradiation in tumor cells and maximizing the delivery 
of HSV-1 to tumor cells and the surrounding brain where tumor-infiltration has occurred may 
form the basis of future clinical gene therapy strategies against malignant gliomas.  
 
6.4. Future Studies 
Inhibition of DNA repair by the HSV protein, ICP0, in combination with IR and chemotherapy 
(chemoradiation), may serve as a therapeutic model for malignant glioma.  Targeting the effects 
of ICP0 within tumor tissue and limiting the surrounding toxicity in the brain will be the focus of 
future studies.  New generation HSV-1 mutants will be produced that selectively express ICP0.  
Synthetic hypoxia-response elements (HREs) and chemotherapy/IR-sensitive enhancers (CArG 
elements) will be used to modify the native HSV-1 ICP0 promoter to create replication-defective 
viruses that selectively express ICP0 with IR, hypoxia, and/or chemotherapy.  Transcriptional 
targeting of ICP0 by IR, hypoxia, and/or chemotherapy will be performed in vitro and in vivo 
after convection-enhanced HSV delivery. 
 A human clinical trial involving the use of the d106 virus in combination with 
chemoradiation will be pursued in the therapy of GBM.  A Phase Ib trial will initially be 
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performed to determine human intracerebral toxicity after CED of a high titer of d106 (109 pfu) 
in patients with recurrent GBM tumors who have failed standard treatments.  At the time of 
surgical resection, 3 to 4 CED catheters will be placed in the periphery of the tumor bed.  
Patients will be randomized to undergo CED of d106 or HBSS within 48 hours after catheter 
placement.  CED of virus or HBSS will be performed over 8 hours. Patients will then undergo a 
conformal radiotherapy boost (20-30 Gy) to the region of brain with tumor within 24 hours after 
CED.  Patients will have serial MRI scans of the brain every 2-4 weeks to determine 
intracerebral toxicity and tumor response.  If safety and efficacy can be established in recurrent 
GBM patients who undergo d106 CED and a radiotherapy boost, then a Phase II clinical study 
will be performed assessing the efficacy of d106 CED in combination with chemoradiation in 
patients with newly diagnosed GBM.  
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